Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Br J Dermatol
    April 2024
  1. MALLBRIS MJ, Jia B, Zhao Y, Kahlenberg JM, et al
    Concomitant Moderate to Severe Cutaneous Lesions Have Marked Impact on Quality of Life in Patients with Active Systemic Lupus Erythematosus: A Cross-Sectional Insight from Two Phase 3 Randomised Clinical Trials in Adults.
    Br J Dermatol. 2024 Apr 30:ljae183. doi: 10.1093.
    >> Share

  2. HALIOUA B, Skayem C, Merhand S, Ben Hayoun Y, et al
    Long-term consequences on stigmatization and disease burden during adulthood among patients with childhood or adolescence-onset atopic dermatitis.
    Br J Dermatol. 2024 Apr 29:ljae176. doi: 10.1093.
    >> Share

  3. O'REILLY M, Paolino A, Pathmarajah P, Ferguson J, et al
    Dupilumab in Chronic Actinic Dermatitis: a retrospective case series.
    Br J Dermatol. 2024 Apr 24:ljae180. doi: 10.1093.
    >> Share

  4. LI Y, He Y, Yang F, Liang R, et al
    GSDME-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation.
    Br J Dermatol. 2024 Apr 24:ljae179. doi: 10.1093.
    >> Share

  5. NIELSEN JB, Kristiansen IS, Thapa S
    Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
    Br J Dermatol. 2024 Apr 24:ljae175. doi: 10.1093.
    >> Share

  6. LEEOLOU MC, Sarin KY, Fiorentino DF
    Filling the Prescription Gap: The Value of Community Support in Psoriasis Management.
    Br J Dermatol. 2024 Apr 18:ljae168. doi: 10.1093.
    >> Share

  7. HUANG D, Zhong X, Jiang Y, Kong L, et al
    Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China.
    Br J Dermatol. 2024 Apr 18:ljae147. doi: 10.1093.
    >> Share


  8. The association between vitamin D levels and psoriasis in people aged 40-79 years.
    Br J Dermatol. 2024;190:e54.
    >> Share


  9. Effectiveness and safety of immunoadsorption in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Br J Dermatol. 2024;190:e53.
    >> Share


  10. Predictors of response to treatment with biologics in people with moderate-to-severe psoriasis.
    Br J Dermatol. 2024;190:e55.
    >> Share


  11. A novel strategy for the treatment of melanoma.
    Br J Dermatol. 2024;190:e51.
    >> Share


  12. Practical guide for epidermolysis bullosa management in the first 4 weeks of life.
    Br J Dermatol. 2024;190:e52.
    >> Share


  13. The Patient Benefit Index for topical treatment (PBI-TOP): a new questionnaire to assess the treatment goals and preferences of people with psoriasis.
    Br J Dermatol. 2024;190:e56.
    >> Share


  14. Deciding on the final set of questions and groups of questions in the Patient-Reported Impact of Dermatological Diseases (PRIDD) tool.
    Br J Dermatol. 2024;190:e57.
    >> Share


  15. Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
    Br J Dermatol. 2024;190:e58.
    >> Share


  16. UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt.
    Br J Dermatol. 2024;190:e59.
    >> Share


  17. 'Gene creams' for genetic diseases?
    Br J Dermatol. 2024;190:e50.
    >> Share

  18. PASSERON T
    A pledge for a better care and consideration of patients with vitiligo.
    Br J Dermatol. 2024;190:614-615.
    >> Share

  19. SAMPOGNA F, Piaserico S
    Deucravacitinib: is there still a place or a need for a new oral agent?
    Br J Dermatol. 2024;190:610-611.
    >> Share

  20. HASAN SB, Bates J, Cannings-John R, Collier F, et al
    Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study.
    Br J Dermatol. 2024;190:775-777.
    >> Share

  21. KYUNG S, Woo S, Kim M, Lee H, et al
    Global burden of vaccine-associated alopecia, 1979-2023: a comprehensive analysis of the international pharmacovigilance database.
    Br J Dermatol. 2024;190:764-767.
    >> Share

  22. MOSS C
    Caring for babies born with epidermolysis bullosa.
    Br J Dermatol. 2024;190:608.
    >> Share

  23. RING HC, Thorsen J, Kirby B, Ingram JR, et al
    Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
    Br J Dermatol. 2024;190:769-771.
    >> Share

  24. FAKIH A, Tannous R, Lajnef M, Seneschal J, et al
    Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score.
    Br J Dermatol. 2024;190:712-717.
    >> Share

  25. HASHIMOTO T, Yamagami J
    Development of a novel treatment for pemphigus and confirmation of its efficacy: a randomized controlled trial of protein A immunoadsorption therapy.
    Br J Dermatol. 2024;190:609.
    >> Share

  26. RIVERA S, Dehner K, Flood A, Dykstra C, et al
    Adverse healthcare experiences are correlated with increased time to diagnosis in women with vulvar inflammatory dermatoses: a retrospective cohort survey.
    Br J Dermatol. 2024;190:761-762.
    >> Share

  27. VAN BEEK N, Eming R, Reuss A, Zillikens D, et al
    Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
    Br J Dermatol. 2024;190:657-667.
    >> Share


  28. The 2024 British Skin Foundation Research Awards are now available.
    Br J Dermatol. 2024;190:778.
    >> Share

  29. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
    A retrospective comparison of early- and late-onset chronic actinic dermatitis: characteristics and management.
    Br J Dermatol. 2024 Apr 16:ljae101. doi: 10.1093.
    >> Share

  30. NASLUND-KOCH C, Skov L
    Shedding light on the smoke: Unraveling the impact of smoking cessation on psoriasis development.
    Br J Dermatol. 2024 Apr 15:ljae163. doi: 10.1093.
    >> Share

  31. PHILLIPS C, Russell E, McNiven A, McPherson T, et al
    A Qualitative Study of the Psychological Morbidity in Paediatric Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Br J Dermatol. 2024 Apr 12:ljae154. doi: 10.1093.
    >> Share

  32. BLANCHARD M, Morren MA, Busschots AM, Hauben E, et al
    Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
    Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093.
    >> Share

  33. SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
    Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
    Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
    >> Share

  34. JONES OT, Matin RN, Walter FM
    Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
    Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
    >> Share

  35. CAO Q, Li M
    GLMN variants cause skin hyperpigmentation: a promising potential therapeutic target.
    Br J Dermatol. 2024 Apr 8:ljae149. doi: 10.1093.
    >> Share

  36. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
    Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
    Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
    >> Share

    March 2024
  37. KIM SR, Choi YG, Jo SJ
    Effect of smoking cessation on psoriasis vulgaris, palmoplantar pustulosis, and generalized pustular psoriasis.
    Br J Dermatol. 2024 Mar 27:ljae130. doi: 10.1093.
    >> Share

  38. SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
    Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
    Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
    >> Share

  39. BENTZ P, Weisshaar E
    Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
    Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
    >> Share

  40. JOHNSON C, Liao W
    Food for thought: A comment on 'Breast-feeding decreases the risk of developing psoriasis through early adulthood'.
    Br J Dermatol. 2024 Mar 26:ljae135. doi: 10.1093.
    >> Share

  41. SOROKIN AV, Gelfand JM
    New Prospective Cohort Study and Mendelian Randomization Analysis Reveals a Link Between Psoriasis and Cardiovascular Risk Trough Elevated Plasma Triglycerides.
    Br J Dermatol. 2024 Mar 22:ljae129. doi: 10.1093.
    >> Share

  42. TALTY R, Richmond R, Micevic G
    Melanoma TIL therapy commences era of cell-based immunotherapies.
    Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
    >> Share


  43. Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
    >> Share

  44. STRANDMOE AL, Bremer J, Diercks GFH, Gostynski A, et al
    Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment.
    Br J Dermatol. 2024 Mar 20:ljae107. doi: 10.1093.
    >> Share

  45. JIANG X, Yang C, Wang Z, Liang L, et al
    Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation.
    Br J Dermatol. 2024 Mar 15:ljae108. doi: 10.1093.
    >> Share


  46. AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
    Br J Dermatol. 2024;190:e46.
    >> Share


  47. Blood monitoring during psoriasis treatment with biologics.
    Br J Dermatol. 2024;190:e47.
    >> Share


  48. Safety of bimekizumab over 3 years in patients with psoriasis.
    Br J Dermatol. 2024;190:e38.
    >> Share


  49. International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
    Br J Dermatol. 2024;190:e40.
    >> Share


  50. Skin barrier dysfunction drives skin inflammation via formylpeptide receptor 1.
    Br J Dermatol. 2024;190:e45.
    >> Share


  51. 2024 British Skin Foundation Small Grants are NOW AVAILABLE.
    Br J Dermatol. 2024;190:603.
    >> Share


  52. Comparison of topical permethrin 5% and benzyl benzoate 25% for treating scabies.
    Br J Dermatol. 2024;190:e39.
    >> Share


  53. Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
    Br J Dermatol. 2024;190:e42.
    >> Share


  54. The relationship between paediatric eczema and cognition.
    Br J Dermatol. 2024;190:e41.
    >> Share


  55. A guide to using the core outcome set for eczema.
    Br J Dermatol. 2024;190:e44.
    >> Share

  56. GARMAN KA, Thoreson N, Strong J, Hallaert P, et al
    Mycophenolate mofetil inhibits Merkel cell carcinoma growth.
    Br J Dermatol. 2024;190:593-595.
    >> Share

  57. CORNMAN HL, Whang KA, Ma E, Aggarwal P, et al
    Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort.
    Br J Dermatol. 2024;190:571-572.
    >> Share

  58. CLAIRE FULLER L, Sunderkotter C
    Scabies therapy update: Should 25% benzyl benzoate emulsion be reconsidered as a first-line agent in classical scabies?
    Br J Dermatol. 2024;190:459-460.
    >> Share

  59. NIELSEN W, Drucker AM
    The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
    Br J Dermatol. 2024;190:462-463.
    >> Share

  60. XIE W, Kong X, Zheng H, Mei H, et al
    Rapid emergence of recalcitrant dermatophytosis caused by a cluster of multidrug-resistant Trichophyton indotineae in China.
    Br J Dermatol. 2024;190:585-587.
    >> Share

  61. NANDA A, Chang YH, Cheng HC, Lai IT, et al
    Autosomal recessive plantar keratoderma with ragged periungual hyperkeratosis caused by a homozygous missense variant in KRT16.
    Br J Dermatol. 2024;190:588-590.
    >> Share

  62. COWPER R
    For itch and insanity.
    Br J Dermatol. 2024;190:568.
    >> Share

  63. BARLOW R, Ahmed A, Fellows J, Goulding J, et al
    Assessing and managing the mental health of people with vitiligo: a UK-wide consultation exercise.
    Br J Dermatol. 2024;190:574-576.
    >> Share

  64. MEYERSBURG D, Hoellwerth M, Brandlmaier M, Handisurya A, et al
    Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial.
    Br J Dermatol. 2024;190:486-491.
    >> Share

  65. MOSCARELLA E, Di Brizzi EV, Alpi P, Arcelli A, et al
    Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensus.
    Br J Dermatol. 2024;190:578-579.
    >> Share

  66. DONHAUSER T, Gabes M, Ozkan E, Masur C, et al
    What do Hyperhidrosis Quality of Life Index (HidroQoL(c)) scores mean? Transferring science into practice by establishing a score banding system.
    Br J Dermatol. 2024;190:519-526.
    >> Share

  67. WAINMAN HE, Chandran NS, Frew JW, Garg A, et al
    Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
    Br J Dermatol. 2024;190:510-518.
    >> Share

  68. GEORGE CD, Lee T, Hollestein LM, Asgari MM, et al
    Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis.
    Br J Dermatol. 2024;190:465-476.
    >> Share

  69. NALDI L, Cassalia F
    Actinic keratosis epidemiology: the good, the bad and the ugly.
    Br J Dermatol. 2024;190:457-458.
    >> Share

  70. OYESIKU L, Dlova N, Ahmed S, Owen DR, et al
    Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward.
    Br J Dermatol. 2024 Mar 13:ljae064. doi: 10.1093.
    >> Share

  71. AALA WJF, Hou PC, Hong YK, Lin YC, et al
    Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ Th2 cells which may contribute to pruritus in lesional skin.
    Br J Dermatol. 2024 Mar 13:ljae110. doi: 10.1093.
    >> Share


  72. Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
    >> Share

  73. CANTISANI C, Taliano A, Longo C, Bortone G, et al
    Dynamic Optical Coherence Tomography and Reflectance Confocal Microscopy of Basal Cell Carcinoma of the Nipple-Areola Complex.
    Br J Dermatol. 2024 Mar 12:ljae104. doi: 10.1093.
    >> Share

  74. ARMATO U, Dal Pra I
    Discovering skin-rejuvenating matrikines - a basic and applied Dermatology new frontier.
    Br J Dermatol. 2024 Mar 12:ljae100. doi: 10.1093.
    >> Share

  75. CHEN GF, Xu S, White MA, Cohen JM, et al
    Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
    Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
    >> Share

  76. RA AG, Littlewood Z, Barton A, Keevil B, et al
    The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
    Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093.
    >> Share

  77. REHBINDER EM, Warnberg Gerdin S, Hoyer A, Bradley M, et al
    Frequent oil-baths and skin barrier during infancy in the PreventADALL study.
    Br J Dermatol. 2024 Mar 6:ljae091. doi: 10.1093.
    >> Share

  78. EL HACHEM M, De Marco R, Soria de Francisco JM, Audouze A, et al
    Ichthyosis: multinational European study on patient characteristics and body sites involved with impact on quality of life.
    Br J Dermatol. 2024 Mar 1:ljae082. doi: 10.1093.
    >> Share

    February 2024
  79. RIBERO S, Quaglino P, Roccuzzo G
    Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
    Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
    >> Share

  80. RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
    Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
    Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
    >> Share

  81. GREVE AM, Wulff AB, Bojesen SE, Nordestgaard BG, et al
    Elevated plasma triglycerides increase risk of psoriasis: A cohort and Mendelian randomization study.
    Br J Dermatol. 2024 Feb 27:ljae089. doi: 10.1093.
    >> Share

  82. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
    Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
    Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
    >> Share

  83. HUGHES O, Thompson AR
    Dealing with Flares in Skin Conditions: How Can We Meet Patient Need?
    Br J Dermatol. 2024 Feb 23:ljae084. doi: 10.1093.
    >> Share


  84. Correction to: How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
    Br J Dermatol. 2024 Feb 21:ljae060. doi: 10.1093.
    >> Share

  85. JARIWALA N, Ozols M, Eckersley A, Mambwe B, et al
    Prediction, screening and characterization of novel bioactive tetra-peptide matrikines for skin rejuvenation.
    Br J Dermatol. 2024 Feb 20:ljae061. doi: 10.1093.
    >> Share

  86. GLEESON D, Naveed M, Moorhead L, McAteer H, et al
    Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multi-stakeholder mixed methods study.
    Br J Dermatol. 2024 Feb 17:ljae068. doi: 10.1093.
    >> Share

  87. BABAKINEJAD P, Lapsley R, Forster L, McPherson S, et al
    Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate to severe psoriasis.
    Br J Dermatol. 2024 Feb 17:ljae069. doi: 10.1093.
    >> Share


  88. Alopecia areata and comorbidities associated with it in Germany.
    Br J Dermatol. 2024;190:e32.
    >> Share


  89. Macrophages dampen skin inflammation after stem cell transplantation.
    Br J Dermatol. 2024;190:e35.
    >> Share


  90. Safety of combination therapy for psoriasis: findings from the BIOBADADERM registry.
    Br J Dermatol. 2024;190:e30.
    >> Share


  91. Comorbidities in people with psoriasis.
    Br J Dermatol. 2024;190:e31.
    >> Share


  92. A clinical trial investigating if antibacterial therapeutic clothing could improve atopic dermatitis.
    Br J Dermatol. 2024;190:e29.
    >> Share


  93. A review of the role of the NLRP1 inflammasome in skin conditions.
    Br J Dermatol. 2024;190:e27.
    >> Share


  94. Greater understanding about the role of a long non-coding RNA in the development of cutaneous squamous cell carcinoma.
    Br J Dermatol. 2024;190:e36.
    >> Share


  95. Results from the Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS).
    Br J Dermatol. 2024;190:e33.
    >> Share


  96. Outcomes that need to be assessed in pyoderma gangrenosum clinical trials.
    Br J Dermatol. 2024;190:e34.
    >> Share

  97. ALABAS OA, Yiu ZZN
    A sprinkle of methotrexate to go with biologics: a safe recipe?
    Br J Dermatol. 2024;190:302-303.
    >> Share

  98. LIU Y, Mo R, Chen Z, Yang Y, et al
    Novel variants in ABCA12 cause erythrokeratodermia variabilis.
    Br J Dermatol. 2024;190:454.
    >> Share

  99. HOPKINS ZH, Chada LMP, Duffin KC
    Defining what matters through core outcomes set development: uniting stakeholder perspectives, empowering patient voices.
    Br J Dermatol. 2024;190:301-302.
    >> Share

  100. BREHON A, Bensefa-Colas L, D'Andrea C, Jeziorski E, et al
    Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.
    Br J Dermatol. 2024;190:445-447.
    >> Share

  101. JACOBSON ME, Rick JW, Gerbens LAA, Baghoomian W, et al
    A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.
    Br J Dermatol. 2024;190:392-401.
    >> Share

  102. KINOSHITA-ISE M
    Updated epidemiology of alopecia areata in Germany: the data tell a lot but hide a lot.
    Br J Dermatol. 2024;190:297-298.
    >> Share

  103. JUNG JM, Cho HS, Kim GH, Won CH, et al
    Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
    Br J Dermatol. 2024;190:432-434.
    >> Share

  104. AUGUSTIN M, Ben-Anaya N, Muller K, Hagenstrom K, et al
    Epidemiology of alopecia areata and population-wide comorbidities in Germany: analysis of longitudinal claims data.
    Br J Dermatol. 2024;190:374-381.
    >> Share

  105. INGRAM JR, Bates J, Cannings-John R, Collier F, et al
    Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study.
    Br J Dermatol. 2024;190:382-391.
    >> Share

  106. GARG A, Mastacouris N, Ingram JR, Strunk A, et al
    Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa.
    Br J Dermatol. 2024;190:427-429.
    >> Share

  107. VYAS J, Johns JR, Ali FM, Singh RK, et al
    A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries.
    Br J Dermatol. 2024;190:315-339.
    >> Share

  108. CAI L, Jiang C, Zhang G, Fang H, et al
    A multicenter, randomized, double-blinded, placebo-controlled, phase ? study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Br J Dermatol. 2024 Feb 15:ljae062. doi: 10.1093.
    >> Share

  109. WAN G, Khattab S, Leung BW, Zhang S, et al
    Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
    Br J Dermatol. 2024 Feb 15:ljae053. doi: 10.1093.
    >> Share

  110. ZHANG J, Schuttelaar MLA
    How can we better address patients' needs in topical psoriasis treatment?
    Br J Dermatol. 2024 Feb 5:ljae046. doi: 10.1093.
    >> Share

  111. KOBYLETZKI LBV, Svensson A
    Long term outcome measures of atopic dermatitis gain importance: a validation study filling a research gap.
    Br J Dermatol. 2024 Feb 5:ljae049. doi: 10.1093.
    >> Share

  112. EGELER MD, Ryll B
    Survival is not enough: understanding the mental burden of cutaneous melanoma.
    Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.
    >> Share

  113. DAS D, Thimjo J, Lebena A, Guo A, et al
    Breast-feeding decreases the risk of developing psoriasis through early adulthood.
    Br J Dermatol. 2024 Feb 2:ljae043. doi: 10.1093.
    >> Share

  114. WEISS M, Ferre VM, Deschamps L, Evrard D, et al
    Detection of alpha-papillomaviruses in extragenital cutaneous squamous cell carcinomas.
    Br J Dermatol. 2024 Feb 2:ljae047. doi: 10.1093.
    >> Share

    January 2024
  115. MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
    Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
    >> Share

  116. DAINTY KN, Thibau IJC, Amog K, Drucker AM, et al
    Towards a patient-centered definition for atopic dermatitis flare: A qualitative study among adults with atopic dermatitis.
    Br J Dermatol. 2024 Jan 30:ljae037. doi: 10.1093.
    >> Share

  117. TRUM NA, Chen L, Zain J, Rosen ST, et al
    Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
    Br J Dermatol. 2024 Jan 29:ljae039. doi: 10.1093.
    >> Share

  118. BERGAMASCHI D
    Improving cancer stem cells killing in malignant melanoma.
    Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.
    >> Share

  119. GROLLEAU C, Walter-Petrich A, Dupin N, Chanal J, et al
    Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicenter retrospective study of 110 patients.
    Br J Dermatol. 2024 Jan 25:ljae032. doi: 10.1093.
    >> Share


  120. Hidradenitis suppurativa: a review with new insights into disease mechanisms and potential future treatments.
    Br J Dermatol. 2024;190:e14.
    >> Share


  121. Comparing systemic treatments for eczema.
    Br J Dermatol. 2024;190:e16.
    >> Share


  122. Risk factors for developing a new primary melanoma in people with a melanoma.
    Br J Dermatol. 2024;190:e15.
    >> Share


  123. Targeting Skp2 in blood vessels may be a promising approach to treat psoriasis.
    Br J Dermatol. 2024;190:e22.
    >> Share


  124. A study using machine learning to help identify subgroups of adults with atopic dermatitis.
    Br J Dermatol. 2024;190:e19.
    >> Share


  125. Omalizumab used to treat bullous pemphigoid resistant to other treatments.
    Br J Dermatol. 2024;190:e23.
    >> Share


  126. Genes associated with nodular melanoma.
    Br J Dermatol. 2024;190:e18.
    >> Share


  127. A decreasing trend of atopic dermatitis among children in Sweden.
    Br J Dermatol. 2024;190:e17.
    >> Share


  128. Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1.
    Br J Dermatol. 2024;190:e20.
    >> Share

  129. ROMO CG, Sarin KY, Blakeley JO
    Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1.
    Br J Dermatol. 2024;190:145-146.
    >> Share

  130. KHAN SS, Fuller LC
    Is there a growing global threat of scabies treatment failure? An opportunity to discuss health inequity within UK dermatology.
    Br J Dermatol. 2024;190:139-140.
    >> Share

  131. FAIRLEY JA, Messingham KAN
    Omalizumab therapy of bullous pemphigoid.
    Br J Dermatol. 2024;190:142-143.
    >> Share

  132. KIM EJ, Reusch DB, Anthony H, Schmidt B, et al
    Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib.
    Br J Dermatol. 2024;190:283-284.
    >> Share

  133. SOEGIHARTO R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, et al
    Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.
    Br J Dermatol. 2024;190:287-289.
    >> Share

  134. CEDERLOF M, Jebril W, Larsson H, Curman P, et al
    Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours.
    Br J Dermatol. 2024;190:284-285.
    >> Share

  135. NIELSEN VW, Ring HC, Holgersen N, Thomsen SF, et al
    Elderly male patients with hidradenitis suppurativa have more severe disease independent of disease duration.
    Br J Dermatol. 2024;190:292-293.
    >> Share

  136. WU W, Chen J, Zhu L, Sha Y, et al
    Janus kinase inhibitor for anti-transcription intermediary factor 1-gamma positive cancer-associated dermatomyositis.
    Br J Dermatol. 2024;190:285-287.
    >> Share

  137. KIRTSCHIG G, Singh S
    Interventions for bullous pemphigoid: summary of a Cochrane Review.
    Br J Dermatol. 2024;190:277-279.
    >> Share

  138. FONJUNGO FE, Barnes LA, Cai ZR, Naik HB, et al
    Longitudinal remote monitoring of hidradenitis suppurativa: a pilot study.
    Br J Dermatol. 2024;190:274-276.
    >> Share

  139. KORTE EWH, Spuls PI, van den Akker PC, Kiritsi D, et al
    Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting.
    Br J Dermatol. 2024;190:268-270.
    >> Share

  140. CHEBANI R, Lombart F, Chaby G, Dadban A, et al
    Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
    Br J Dermatol. 2024;190:258-265.
    >> Share

  141. KRUEGER JG, Frew J, Jemec GBE, Kimball AB, et al
    Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
    Br J Dermatol. 2024;190:149-162.
    >> Share

  142. MBUAGBAW L, Sadeghirad B, Morgan RL, Mertz D, et al
    Failure of scabies treatment: a systematic review and meta-analysis.
    Br J Dermatol. 2024;190:163-173.
    >> Share

  143. PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
    Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
    Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
    >> Share

  144. LEBWOHL M, Warren RB, Sofen H, Imafuku S, et al
    Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
    Br J Dermatol. 2024 Jan 16:ljae014. doi: 10.1093.
    >> Share

  145. PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
    Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
    Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
    >> Share

  146. BLOME C, Hulswitt L, Meineke A, Augustin M, et al
    Goals and benefits in topical treatment for psoriasis: Development and pilot validation of a patient-reported outcomes tool (PBI-TOP).
    Br J Dermatol. 2024 Jan 12:ljad484. doi: 10.1093.
    >> Share

  147. COCCIMIGLIO M, Chiodo F, van Kooyk Y
    The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
    Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
    >> Share

  148. KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
    Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
    Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
    >> Share

  149. FUNCH AB, Glindvad Ahlstrom M, Johansen JD, Geisler C, et al
    Neutrophil Infiltration in Allergic Contact Dermatitis to Nickel.
    Br J Dermatol. 2024 Jan 4:ljad499. doi: 10.1093.
    >> Share

  150. LI Q, Tsoi LC
    Biologic survival: a novel approach for drug efficacy estimation in psoriasis.
    Br J Dermatol. 2024 Jan 4:ljae007. doi: 10.1093.
    >> Share

  151. YOO LJH, Stefanovic N, Watchorn RE
    Atopic Dermatitis and Autism: Tactile Hypersensitivity Impeding on Topical Therapy Use.
    Br J Dermatol. 2024 Jan 4:ljae005. doi: 10.1093.
    >> Share

  152. SAAD R, Duipmans J, Yerlett N, Plevey K, et al
    Neonatal Epidermolysis Bullosa: a clinical practice guideline.
    Br J Dermatol. 2024 Jan 4:ljae006. doi: 10.1093.
    >> Share

  153. SMITH KA, Hiyoshi A, Vingeliene S, von Kobyletzki L, et al
    Atopic dermatitis and cognitive function: a sibling comparison study among males in Sweden.
    Br J Dermatol. 2024 Jan 3:ljae004. doi: 10.1093.
    >> Share

    December 2023
  154. GURI-LAMCE I, AlRokh Y, Kim Y, Maeshima R, et al
    Topical gene editing therapeutics using lipid nanoparticles: "gene creams" for genetic skin diseases?
    Br J Dermatol. 2023 Dec 27:ljad528. doi: 10.1093.
    >> Share

  155. JOHNSON C, Smith P, Haran K, Kranyak A, et al
    Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'.
    Br J Dermatol. 2023 Dec 27:ljad529. doi: 10.1093.
    >> Share

  156. JEREMIAN R, Malinowski A, Lytvyn Y, Georgakopoulos JR, et al
    Skin photoaging following sun exposure is associated with decreased epigenetic and biological age and correlates with basal cell carcinoma phenotype.
    Br J Dermatol. 2023 Dec 22:ljad527. doi: 10.1093.
    >> Share


  157. Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years.
    Br J Dermatol. 2023;190:e2.
    >> Share


  158. A pharmacogenetic study of psoriasis supports the association between a gene (KLK7) and treatment response.
    Br J Dermatol. 2023;190:e8.
    >> Share


  159. Greater understanding about differences in the long-term course of eczema and their risk factors in children.
    Br J Dermatol. 2023;190:e5.
    >> Share


  160. A new method to measure facial depigmentation in vitiligo.
    Br J Dermatol. 2023;190:e7.
    >> Share


  161. A study about how many people around the world have atopic dermatitis.
    Br J Dermatol. 2023;190:e6.
    >> Share


  162. A study looking at a possible new drug, HB0017, for the treatment of psoriasis.
    Br J Dermatol. 2023;190:e3.
    >> Share


  163. Hidradenitis suppurativa in older adults.
    Br J Dermatol. 2023;190:e11.
    >> Share


  164. Genetics and melanoma screening.
    Br J Dermatol. 2023;190:e4.
    >> Share


  165. A short RNA molecule and tumour aggressiveness in people with epidermolysis bullosa.
    Br J Dermatol. 2023;190:e9.
    >> Share


  166. The role of enhancers in eczema and psoriasis.
    Br J Dermatol. 2023;190:e1.
    >> Share

  167. O'SHAUGHNESSY RFL
    Why are squamous cancers so aggressive in recessive dystrophic epidermolysis bullosa? Can we find new therapeutic approaches?
    Br J Dermatol. 2023;190:7-8.
    >> Share

  168. MARQUEZ DG, Sadeghi NB, Westerkam LL, Blum FR, et al
    A survey-based study on experiences with and perspectives toward medical providers among patients with hidradenitis suppurativa.
    Br J Dermatol. 2023;190:127-129.
    >> Share

  169. ELEFTHERIADOU V, Seneschal J
    Assessment of treatment response on facial vitiligo, a step forward. But what about the neck?
    Br J Dermatol. 2023;190:5-6.
    >> Share

  170. SENENT-VALERO M, Matijasevich A, Jara-Rico N, Sivera F, et al
    Drug survival of metformin in patients with hidradenitis suppurativa.
    Br J Dermatol. 2023;190:125-127.
    >> Share

  171. TAN E, Kennedy H, Rademaker M
    When science and evidence is not enough: challenging the recommendations from the Commission on Human Medicines Isotretinoin Expert Working Group.
    Br J Dermatol. 2023;190:116-117.
    >> Share

  172. ILLMER J, Zauner R, Pinon Hofbauer J, Wimmer M, et al
    MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
    Br J Dermatol. 2023;190:80-93.
    >> Share

  173. BUONTEMPO MG, Sicco KL, Shapiro J
    Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children'.
    Br J Dermatol. 2023;190:135.
    >> Share

  174. CHORAGUDI SC, Andrade LF, Yosipovitch G
    Pruritus is associated with longer hospital stays and higher costs in psychiatric inpatients from the USA National Inpatient Sample (2012-2015): a cross-sectional study.
    Br J Dermatol. 2023;190:119-120.
    >> Share

  175. ELEFTHERIADOU V, Hamzavi I, Bae JM, Ezzedine K, et al
    Roadmap to VIRTUAL-GLOBAL: coordinating VItiligo RegisTries for adUlts And chiLdren internationally.
    Br J Dermatol. 2023;190:114-116.
    >> Share

  176. VAN DER WEIJDEN DAY, Koerts NDK, van Munster BC, van der Zee HH, et al
    Hidradenitis suppurativa tarda: defining an understudied elderly population.
    Br J Dermatol. 2023;190:105-113.
    >> Share

  177. MARIN DIT BERTOUD Q, Bertold C, Ezzedine K, Pandya AG, et al
    Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm.
    Br J Dermatol. 2023;190:62-69.
    >> Share

  178. NARAHARI SR, Aggithaya MG, Ryan TJ, Muralidharan K, et al
    Self-care treatment for lymphoedema of lymphatic filariasis using integrative medicine.
    Br J Dermatol. 2023;190:94-104.
    >> Share

  179. ASFOUR L, Bokhari L, Bhoyrul B, Eisman S, et al
    Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children with baricitinib': authors' reply.
    Br J Dermatol. 2023;190:136-137.
    >> Share

  180. TIERNEY E, Evans P, Broderick V, Wynn R, et al
    Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Dec 20:ljad526. doi: 10.1093.
    >> Share

  181. THOMAS KS, Howells L, Leshem YA, Simpson EL, et al
    How to use the HOME Core Outcome Set for atopic dermatitis trials - a users' guide.
    Br J Dermatol. 2023 Dec 20:ljad497. doi: 10.1093.
    >> Share

  182. LEFRANCOIS P, Doueidari Z, Kleiner O, Manion R, et al
    Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.
    Br J Dermatol. 2023 Dec 19:ljad387. doi: 10.1093.
    >> Share

  183. ABDI P, Haq Z, Diaz MJ, Maibach HI, et al
    Infectious disease among adults with allergic contact dermatitis: A propensity score-matched case-control study.
    Br J Dermatol. 2023 Dec 19:ljad504. doi: 10.1093.
    >> Share

  184. NASLUND-KOCH C, Skov L
    New insights in the complex relationship between psoriasis and vitamin D - and not to forget -obesity!
    Br J Dermatol. 2023 Dec 19:ljad506. doi: 10.1093.
    >> Share

  185. EGGERMONT CJ, Eggermont AMM
    Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
    Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.
    >> Share

  186. CONTI A, Paolinelli M
    A new approach in monitoring blood tests in anti-TNF-alpha therapies in psoriasis.
    Br J Dermatol. 2023 Dec 13:ljad490. doi: 10.1093.
    >> Share

  187. ORTONNE N
    How to score the impact of treatment on cutaneous neurofibromas in clinical trials?
    Br J Dermatol. 2023 Dec 12:ljad492. doi: 10.1093.
    >> Share

  188. ISKANDAR IYK, Gawkrodger DJ, Gittins M, Byrne L, et al
    Trends in occupational and work-related contact dermatitis attributed to nickel, chromium and cobalt in the UK: findings from The Health and Occupation Research network 1996-2019.
    Br J Dermatol. 2023 Dec 7:ljad488. doi: 10.1093.
    >> Share

  189. THORLACIUS L, Theut Riis P, Musaeus KD, Saunte DM, et al
    Severity rating of specific skin lesions in hidradenitis suppurativa - the patient perspective.
    Br J Dermatol. 2023 Dec 7:ljad491. doi: 10.1093.
    >> Share

  190. SOCKLER PG, Hooper SR, Abuabara K, Ma EZ, et al
    Atopic dermatitis, cognitive function, and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort.
    Br J Dermatol. 2023 Dec 7:ljad486. doi: 10.1093.
    >> Share

  191. ALABAS OA, Mason KJ, Yiu ZZN, Warren RB, et al
    The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Br J Dermatol. 2023 Dec 5:ljad481. doi: 10.1093.
    >> Share

  192. WEIDINGER S, Simpson EL, Silverberg JI, Barbarot S, et al
    Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
    Br J Dermatol. 2023 Dec 4:ljad449. doi: 10.1093.
    >> Share

  193. BONE M, Inman GJ
    Exon specific oncogenic function of the long non-coding RNA PVT1 in cutaneous squamous cell carcinoma, a promising potential therapeutic target.
    Br J Dermatol. 2023 Dec 1:ljad476. doi: 10.1093.
    >> Share

    November 2023
  194. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.
    >> Share

  195. YU J
    Are perinatal antibiotics responsible for atopic dermatitis? The Debate Rages On.
    Br J Dermatol. 2023 Nov 30:ljad477. doi: 10.1093.
    >> Share

  196. WANG Y, Arbiser JL
    Skp2: A new therapeutic target of psoriasis.
    Br J Dermatol. 2023 Nov 30:ljad479. doi: 10.1093.
    >> Share

  197. KIM M, Choi Y, Lee M, Kang J, et al
    Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea.
    Br J Dermatol. 2023 Nov 30:ljad478. doi: 10.1093.
    >> Share

  198. JENSSEN M, Furberg AS, Jorde R, Wilsgaard T, et al
    The association between serum 25-hydroxyvitamin D levels and psoriasis in a large population-based cohort, a cross-sectional analysis of The Tromso Study 2015-16.
    Br J Dermatol. 2023 Nov 28:ljad472. doi: 10.1093.
    >> Share

  199. DOBEL T, Schakel K
    Transcriptional landscape of macrophages in cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Nov 28:ljad458. doi: 10.1093.
    >> Share

  200. GUENIN S, Andrews E, Lebwohl MG
    Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis.
    Br J Dermatol. 2023 Nov 27:ljad473. doi: 10.1093.
    >> Share

  201. DAND N, Ramessur R
    New analyses exploring multimorbidity in psoriasis.
    Br J Dermatol. 2023 Nov 27:ljad475. doi: 10.1093.
    >> Share

  202. STROBL J, Gail LM, Krecu L, Madad S, et al
    Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Nov 27:ljad402. doi: 10.1093.
    >> Share

  203. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    >> Share

  204. SHOIMER I, Kleiner O, Manion R, Dutz J, et al
    Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.
    Br J Dermatol. 2023 Nov 21:ljad391. doi: 10.1093.
    >> Share

  205. SHAO S, Sun Z, Chu M, Chen J, et al
    FPR1 contributes to epidermal barrier dysfunction-induced skin inflammation through NLRC4-dependent keratinocyte activation.
    Br J Dermatol. 2023 Nov 18:ljad455. doi: 10.1093.
    >> Share

  206. KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
    Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
    Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.
    >> Share

  207. RAJ C, Singh S, Gupta A
    Psychosocial Impact of Severe Autosomal Recessive Congenital Ichthyosis.
    Br J Dermatol. 2023 Nov 17:ljad456. doi: 10.1093.
    >> Share

  208. CAZZANIGA S, Simon D
    Decoding Atopic Dermatitis: Unveiling Phenotypes Through Data-Driven Methods.
    Br J Dermatol. 2023 Nov 17:ljad453. doi: 10.1093.
    >> Share

  209. DESSINIOTI C, Stratigos AJ
    Decoding the nodular melanoma subtype- what about genetics?
    Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.
    >> Share


  210. Survival trends in people with melanoma in Sweden.
    Br J Dermatol. 2023;189:e108.
    >> Share


  211. Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
    Br J Dermatol. 2023;189:e106.
    >> Share


  212. A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
    Br J Dermatol. 2023;189:e105.
    >> Share


  213. Short anagen hair syndrome is caused by mutations in the WNT10A gene and has a genetic overlap with male pattern hair loss.
    Br J Dermatol. 2023;189:e112.
    >> Share


  214. A roadmap to help with the adoption of core outcome sets in eczema clinical trials.
    Br J Dermatol. 2023;189:e109.
    >> Share


  215. There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib.
    Br J Dermatol. 2023;189:e104.
    >> Share

  216. AHMED A, Eleftheriadou V
    Global VALIANT study: 'lifting the lid' on disappointment and frustration with the lack of effective treatment for vitiligo.
    Br J Dermatol. 2023;189:e99-e102.
    >> Share

  217. STERN RS
    The limitations of persistence as a measure of efficacy of biologic therapies.
    Br J Dermatol. 2023;189:e100-e101.
    >> Share

  218. CESARATO N, Schwieger-Briel A, Gossmann Y, Henne SK, et al
    Short anagen hair syndrome: association with mono- and biallelic variants in WNT10A and a genetic overlap with male pattern hair loss.
    Br J Dermatol. 2023;189:741-749.
    >> Share

  219. REVANKAR RR, Blum F, Yeung H, Patel HA, et al
    Factors influencing patient experience during incision and drainage procedures in hidradenitis suppurativa: an analysis of patient-reported outcomes.
    Br J Dermatol. 2023;189:779-780.
    >> Share

  220. PETRASCA A, Hambly R, Kearney N, Smith CM, et al
    Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa.
    Br J Dermatol. 2023;189:730-740.
    >> Share

  221. KUMAR S, Hausen J, Sivalingam S, Humbatova A, et al
    Altered Notch signalling in Dowling-Degos disease: a transcriptomic insight into disease pathogenesis.
    Br J Dermatol. 2023;189:772-774.
    >> Share

  222. YOU Z, Ran Y
    Symmetrical sporotrichosis on the face: pathogen spread from the nose along both sides of facial lymphatic vessels?
    Br J Dermatol. 2023;189:784-785.
    >> Share

  223. SIA T, Webb T, Li S, Moskatel LS, et al
    An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea.
    Br J Dermatol. 2023;189:776-778.
    >> Share

  224. LESHEM YA, Simpson EL, Apfelbacher C, Spuls PI, et al
    The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap.
    Br J Dermatol. 2023;189:710-718.
    >> Share

  225. CHERREZ-OJEDA I, Thomsen SF, Gimenez-Arnau A
    Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile.
    Br J Dermatol. 2023;189:766-767.
    >> Share

  226. MAGHFOUR J, Dzuali F, Ezekwe N, Gordon J, et al
    Evaluating the efficacy of continuous wave carbon dioxide laser therapy in conjunction with biologics for the management of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:764-783.
    >> Share


  227. Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
    Br J Dermatol. 2023 Nov 16:ljad442. doi: 10.1093.
    >> Share


  228. The skin has memory: how it works and how to help it forget.
    Br J Dermatol. 2023;189:e103.
    >> Share


  229. A study about the presence of Staphylococcus aureus growth at birth and at 2 months of age in children who developed atopic dermatitis in the first 2 years of life.
    Br J Dermatol. 2023;189:e107.
    >> Share


  230. A non-invasive method using tape stripping for whole-genome skin profiling.
    Br J Dermatol. 2023;189:e113.
    >> Share


  231. The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa.
    Br J Dermatol. 2023;189:e111.
    >> Share


  232. Interleukin-17A-expressing mast cells in hidradenitis suppurativa.
    Br J Dermatol. 2023;189:e110.
    >> Share

  233. SACEDON R, de Arriba MC, Martinez-Santamaria L, Maseda R, et al
    Gluten-sensitive enteropathy in recessive dystrophic epidermolysis bullosa.
    Br J Dermatol. 2023;189:774-776.
    >> Share

  234. CHU CB, Yang CC, Hsueh YY, Chen PC, et al
    Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:719-729.
    >> Share

  235. GIAMARELLOS-BOURBOULIS EJ
    Interleukin-17A derived from mast cells: evidence for an autoinflammatory loop in hidradenitis suppurativa?
    Br J Dermatol. 2023;189:651-652.
    >> Share

  236. ONOUFRIADIS A
    WNT10A gene variants at the root of short anagen hair syndrome.
    Br J Dermatol. 2023;189:653-654.
    >> Share

  237. KING B, Shapiro J, Ohyama M, Egeberg A, et al
    When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
    Br J Dermatol. 2023;189:666-673.
    >> Share

  238. MASON KJ, Alabas OA, Dand N, Warren RB, et al
    Characteristics of "Super-Responders" and "Super-Non-Responders" to First Biologic Monotherapy for Psoriasis: A Nested Case-control Study.
    Br J Dermatol. 2023 Nov 11:ljad446. doi: 10.1093.
    >> Share

  239. WAN J
    Changes in the epidemiology of atopic dermatitis: putting them into context.
    Br J Dermatol. 2023 Nov 11:ljad443. doi: 10.1093.
    >> Share

  240. GORDON KB, Langley RG, Warren RB, Okubo Y, et al
    Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials.
    Br J Dermatol. 2023 Nov 10:ljad429. doi: 10.1093.
    >> Share

  241. JUNG SY, Han K, Jung JH, Park H, et al
    Cumulative exposure to metabolic syndrome affects the risk of psoriasis differently according to age group: a nationwide cohort study in S. Korea.
    Br J Dermatol. 2023 Nov 9:ljad441. doi: 10.1093.
    >> Share

  242. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
    Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.
    >> Share

  243. SMIT AK, Cust AE
    Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
    Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.
    >> Share

  244. YOSIPOVITCH G, Lio PA, Rosmarin D, Serra-Baldrich E, et al
    Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
    Br J Dermatol. 2023 Nov 6:ljad435. doi: 10.1093.
    >> Share

  245. RAGAMIN A, Schappin R, de Graaf M, Tupker RA, et al
    The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial).
    Br J Dermatol. 2023 Nov 4:ljad437. doi: 10.1093.
    >> Share

  246. JUMONVILLE G, Hong D, Khan A, DeWan A, et al
    Digital biobanks are underutilized in dermatology and create opportunities to reduce the burden of skin disease.
    Br J Dermatol. 2023 Nov 4:ljad439. doi: 10.1093.
    >> Share

  247. SHIMON SV, Desai K, Miteva M, Nadji M, et al
    High Expression of Interleukin-17A in Cutaneous Sarcoidosis.
    Br J Dermatol. 2023 Nov 4:ljad438. doi: 10.1093.
    >> Share

  248. DOOLAN BJ, McGrath JA, Mellerio JE
    Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critical appraisal.
    Br J Dermatol. 2023 Nov 4:ljad433. doi: 10.1093.
    >> Share

  249. HAIDER S, Granell R, Curtin JA, Holloway JW, et al
    Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.
    Br J Dermatol. 2023 Nov 3:ljad326. doi: 10.1093.
    >> Share

  250. MELNIK BC
    Metformin attenuates mechanistic target of rapamycin complex 1/hypoxia-inducible factor-1alpha-driven glycolysis reducing keratinocyte and T helper 17 cell proliferation in hyperproliferative inflammatory skin diseases.
    Br J Dermatol. 2023 Nov 2:ljad362. doi: 10.1093.
    >> Share

  251. LI C, Sun C, Mahapatra KD, Riihila P, et al
    Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity.
    Br J Dermatol. 2023 Nov 1:ljad419. doi: 10.1093.
    >> Share

    October 2023
  252. KAWSAR A, Hussain K, Fearfield L
    How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
    Br J Dermatol. 2023;189.
    >> Share

  253. HUGHES O, Bewley A
    Is it really ever 'just acne'? Considering the psychodermatology of acne.
    Br J Dermatol. 2023;189.
    >> Share

  254. AHMED A, Fearfield L, Griffiths TW
    Resilience in skin disease.
    Br J Dermatol. 2023;189.
    >> Share

  255. GRIFFITHS TW, Watson REB, Langton AK
    Skin ageing and topical rejuvenation strategies.
    Br J Dermatol. 2023;189.
    >> Share

  256. CHIESA FUXENCH Z, Mitra N, Del Pozo D, Hoffstad O, et al
    In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.
    Br J Dermatol. 2023 Oct 28:ljad428. doi: 10.1093.
    >> Share

  257. OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
    International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
    Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
    >> Share

  258. CALABRESE L, Fiocco Z, Mellett M, Aoki R, et al
    The Role of NLRP1 Inflammasome in Skin Cancer and Inflammatory Skin Diseases.
    Br J Dermatol. 2023 Oct 27:ljad421. doi: 10.1093.
    >> Share


  259. Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells.
    Br J Dermatol. 2023;189:e98.
    >> Share


  260. Lifetime burden of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2023;189:e92.
    >> Share


  261. Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial.
    Br J Dermatol. 2023;189:e90.
    >> Share


  262. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;189:e97.
    >> Share


  263. Views on vitiligo disease course and treatment among people living with vitiligo and healthcare providers worldwide.
    Br J Dermatol. 2023;189:e94.
    >> Share


  264. Understanding the biology of cutaneous squamous cell carcinoma.
    Br J Dermatol. 2023;189:e96.
    >> Share


  265. Comparison of biologic treatments in psoriasis using treatment duration.
    Br J Dermatol. 2023;189:e93.
    >> Share


  266. Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:e95.
    >> Share


  267. Comparison of risankizumab with apremilast for the treatment of moderate psoriasis.
    Br J Dermatol. 2023;189:e91.
    >> Share

  268. OFENLOCH RF
    Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire.
    Br J Dermatol. 2023;189:506-507.
    >> Share

  269. SUH-YUN JOH C, Jeong S, Lee C, Lee HJ, et al
    Spatial transcriptomic profiling reveals the pathophysiology of early-stage hidradenitis suppurativa.
    Br J Dermatol. 2023;189:643-645.
    >> Share

  270. KUMAR N, Pourang A, Ezekwe N, Parks-Miller A, et al
    A method for assessing rater reliability in applying the Vitiligo Area Scoring Index.
    Br J Dermatol. 2023;189:645-647.
    >> Share

  271. CHENG Q, Yang F, Xue R, Wang H, et al
    Postzygotic gain-of-function variants in FGFR2 in two patients with hair follicle naevus.
    Br J Dermatol. 2023;189:641-643.
    >> Share

  272. SHIELDS A, Barbieri JS
    Effectiveness of spironolactone for women with acne vulgaris (SAFA) trial: a critically appraised topic.
    Br J Dermatol. 2023;189:509-510.
    >> Share

  273. HAMZAVI IH, Bibeau K, Grimes P, Harris JE, et al
    Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study.
    Br J Dermatol. 2023;189:569-577.
    >> Share

  274. INGEN-HOUSZ-ORO S
    Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure.
    Br J Dermatol. 2023;189:505-506.
    >> Share

  275. LIU Y, Li Q, Chu C, Zhou Y, et al
    Insights into Stevens-Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life.
    Br J Dermatol. 2023;189:648.
    >> Share

  276. ZHANG J, Ragamin A, Romeijn GLE, Loman L, et al
    Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:578-587.
    >> Share

  277. CHEN GF, Shaw KS, Sanchez-Melendez S, Vleugels RA, et al
    Increased risk of depression in patients with discoid lupus erythematosus: a nested, case-control study in the All of Us Research Program.
    Br J Dermatol. 2023;189:628-629.
    >> Share

  278. WELFRINGER-MORIN A, Bataille P, Drummond D, Bellon N, et al
    Comparison of idiopathic and drug-induced epidermal necrolysis in children.
    Br J Dermatol. 2023;189:631-633.
    >> Share

  279. LI D, Technau-Hafsi K, Giehl K, Hoeger PH, et al
    Targeted anti-interleukin-17 therapy for linear porokeratosis.
    Br J Dermatol. 2023;189:630-631.
    >> Share

  280. SOW Y, Salame N, Siira MR, Flowers N, et al
    Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study.
    Br J Dermatol. 2023;189:624-626.
    >> Share

  281. FERTITTA L, Bergqvist C, Sarin K, Plotkin SR, et al
    A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
    Br J Dermatol. 2023 Oct 25:ljad397. doi: 10.1093.
    >> Share

  282. CHALITSIOS CV, Meena D, Manou M, Papagiannopoulos C, et al
    Multiple long-term conditions in people with psoriasis: a latent class and bidirectional Mendelian randomisation analysis.
    Br J Dermatol. 2023 Oct 24:ljad410. doi: 10.1093.
    >> Share

  283. BERGERON A, Nessim C, Kleiner O, Manion R, et al
    SkIN Canada Priority Setting Initiative ranks the Top Ten evidence uncertainties for Merkel cell carcinoma.
    Br J Dermatol. 2023 Oct 21:ljad398. doi: 10.1093.
    >> Share

  284. VALLEEKANTHAN M, Cree H
    Challenges in adult services for a young adult with a rare skin disease.
    Br J Dermatol. 2023 Oct 21:ljad403. doi: 10.1093.
    >> Share

  285. NYMAND L, Nielsen ML, Vittrup I, Halling AS, et al
    Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
    Br J Dermatol. 2023 Oct 18:ljad401. doi: 10.1093.
    >> Share

  286. XIE X, Cui Q, Jiang T, Zhao Z, et al
    A Critical Role of Endothelial Skp2/PTEN Axis in Angiogenesis and Psoriasis.
    Br J Dermatol. 2023 Oct 18:ljad399. doi: 10.1093.
    >> Share

  287. LLUCH-GALCERA JJ, Carrascosa JM, Gonzalez-Quesada A, Rivera-Diaz R, et al
    Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
    Br J Dermatol. 2023 Oct 17:ljad382. doi: 10.1093.
    >> Share

  288. DRUCKER AM, Lam M, Elsawi R, Prieto-Merino D, et al
    Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093.
    >> Share

  289. COLVIN A, Petukhova L
    Who has skin in the game? Expanding patient opportunities for research engagement is a win-win for dermatology.
    Br J Dermatol. 2023 Oct 13:ljad394. doi: 10.1093.
    >> Share

  290. BERGQVIST C
    Is there room for another Anti-IL-17 in the Crowded Psoriasis Therapeutic Landscape?
    Br J Dermatol. 2023 Oct 12:ljad383. doi: 10.1093.
    >> Share

  291. MURPHY MJ, Hwang E, Singh K, Lee T, et al
    Machine learning analysis of pre-treatment skin biopsies predicts non-response to dupilumab in patients with eczematous dermatitis.
    Br J Dermatol. 2023 Oct 11:ljad389. doi: 10.1093.
    >> Share

  292. HAUGAARD JH, Thein D, Egeberg A
    Characteristics and Prognosis in First-Time Hospitalized Generalized Pustular Psoriasis Patients: Insights from National Databases.
    Br J Dermatol. 2023 Oct 7:ljad384. doi: 10.1093.
    >> Share

  293. AUTIER P
    Melanoma incidence and COVID-19 lockdowns in the Netherlands.
    Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.
    >> Share

    September 2023
  294. AF KLINTEBERG M, Winberg A, Andersson M, Ronmark E, et al
    Decreasing prevalence of atopic dermatitis among Swedish schoolchildren. Three repeated population-based surveys.
    Br J Dermatol. 2023 Sep 30:ljad370. doi: 10.1093.
    >> Share

  295. REYNAUD B, Jacquemus J, Chabaud S, Ouldbey Y, et al
    Benefit of skin surgical revision in high-risk basal cell carcinoma according to histopathological margins.
    Br J Dermatol. 2023 Sep 28:ljad372. doi: 10.1093.
    >> Share

  296. STARK MS, Sturm RA, Pan Y, Smit DJ, et al
    Assessing the genetic risk of nodular melanoma using a candidate gene approach.
    Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
    >> Share

  297. SAKAI A, Shinkuma S, Miura N, Deguchi T, et al
    Possible relation of cathepsin C activity and seasonal fluctuation of skin lesions in Papillon-Lefevre syndrome.
    Br J Dermatol. 2023 Sep 27:ljad373. doi: 10.1093.
    >> Share


  298. Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways.
    Br J Dermatol. 2023 Sep 23:ljad346. doi: 10.1093.
    >> Share


  299. Correction to: Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
    Br J Dermatol. 2023 Sep 23:ljad340. doi: 10.1093.
    >> Share

  300. SMITH CH, Yiu ZZN, Bale T, Burden AD, et al
    British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023 - a pragmatic update.
    Br J Dermatol. 2023 Sep 22:ljad347. doi: 10.1093.
    >> Share

  301. TOLAND AE
    Expanding the feasibility of large genomics skin studies using epidermal DNA collected via tape-stripping.
    Br J Dermatol. 2023 Sep 22:ljad360. doi: 10.1093.
    >> Share

  302. FLOHR C, Rosala-Hallas A, Jones AP, Beattie P, et al
    Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial.
    Br J Dermatol. 2023 Sep 19:ljad281. doi: 10.1093.
    >> Share


  303. The risk of deep-vein blood clots in people with atopic dermatitis (eczema).
    Br J Dermatol. 2023;189:e75.
    >> Share


  304. A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors.
    Br J Dermatol. 2023;189:e69.
    >> Share


  305. Gaining a better understanding of the causes of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:e77.
    >> Share


  306. Clinical trial results for treatment of psoriasis with izokibep.
    Br J Dermatol. 2023;189:e70.
    >> Share


  307. How common is generalized pustular psoriasis in Malaysia?
    Br J Dermatol. 2023;189:e73.
    >> Share


  308. Once-daily roflumilast foam for treating scalp and body psoriasis.
    Br J Dermatol. 2023;189:e71.
    >> Share


  309. Eleven recommendations to support mental health in children and young people with skin conditions.
    Br J Dermatol. 2023;189:e78.
    >> Share

  310. HERBERT S, Haughton R, Liakos W, Wang J, et al
    A qualitative exploration of patient experiences in pyoderma gangrenosum.
    Br J Dermatol. 2023;189:496-498.
    >> Share

  311. SUHRKAMP I, Gerdes S
    The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?
    Br J Dermatol. 2023;189:365-366.
    >> Share

  312. MARONESE CA, Ingram JR, Marzano AV
    Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?
    Br J Dermatol. 2023;189:467-468.
    >> Share

  313. CHANDLER DJ, Yamamoto R, Hay RJ
    Use of direct microscopy to diagnose superficial mycoses: a survey of UK dermatology practice.
    Br J Dermatol. 2023;189:480-481.
    >> Share

  314. ORTNER VK, Zibert JR, Manole I, Mondragon AC, et al
    Agreement and reliability of remote assessment of actinic keratosis: a proof-of-concept study using smartphone photographs.
    Br J Dermatol. 2023;189:474-475.
    >> Share

  315. BRANS R
    Promising results for treatment of severe chronic hand eczema with dupilumab.
    Br J Dermatol. 2023;189:360-361.
    >> Share

  316. HARMAN KE, Barha J, Chalmers JR, Dart JKG, et al
    The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership.
    Br J Dermatol. 2023;189:469-498.
    >> Share

  317. VOORBERG AN, Kamphuis E, Christoffers WA, Schuttelaar MLA, et al
    Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Br J Dermatol. 2023;189:400-409.
    >> Share

  318. VAN DOORN R
    Multiple Primary Melanoma: Risk Factors Reviewed.
    Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.
    >> Share

  319. NAKAHARA T, Fujita H, Tajima Y, Arima K, et al
    Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control among individuals with atopic dermatitis in Japan.
    Br J Dermatol. 2023 Sep 15:ljad344. doi: 10.1093.
    >> Share


  320. Patient assessment of psoriasis severity.
    Br J Dermatol. 2023;189:e76.
    >> Share


  321. Features of very thin melanoma that predict lymph node involvement.
    Br J Dermatol. 2023;189:e74.
    >> Share


  322. Correction to: Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the U.K. and Denmark, and to: Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the UK and Denmark.
    Br J Dermatol. 2023 Sep 14:ljad338. doi: 10.1093.
    >> Share

  323. TIAN J, Zhang D, Yang Y, Huang Y, et al
    The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.
    Br J Dermatol. 2023 Sep 14:ljad339. doi: 10.1093.
    >> Share

  324. GUERRERO-JUAREZ CF, Goyal PK, Amber KT
    Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
    Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.
    >> Share

  325. GERDES S, Staubach P, Dirschka T, Wetzel D, et al
    Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.
    Br J Dermatol. 2023 Sep 12:ljad186. doi: 10.1093.
    >> Share

  326. PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
    Does genetic risk modify the effect of skin screening on melanoma detection rates?
    Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
    >> Share

  327. VEYSEY E
    Risankizumab vs. apremilast in the era of skin clearance.
    Br J Dermatol. 2023 Sep 6:ljad328. doi: 10.1093.
    >> Share

  328. ZHANG H, Patrick MT, Tejasvi T, Sarkar MK, et al
    Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in TNF signaling.
    Br J Dermatol. 2023 Sep 6:ljad332. doi: 10.1093.
    >> Share

  329. FUXENCH ZCC, Wan J, Wang S, Syed MN, et al
    Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom.
    Br J Dermatol. 2023 Sep 6:ljad325. doi: 10.1093.
    >> Share

  330. NGUYEN V, Gao C, Hochman ML, Kravitz J, et al
    Endothelial cells differentiated from patient dermal fibroblast-derived induced pluripotent stem cells resemble vascular malformations of Port Wine Birthmark.
    Br J Dermatol. 2023 Sep 6:ljad330. doi: 10.1093.
    >> Share

  331. JIANG C, Du Y, Liu X, Wang J, et al
    Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody targeting IL-17A, in healthy subjects and patients with moderate to severe plaque psoriasis (PsO).
    Br J Dermatol. 2023 Sep 5:ljad315. doi: 10.1093.
    >> Share

  332. RIDDLE AO, Jambusaria-Pahlajani A
    Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients: A Critically-appraised Research Paper.
    Br J Dermatol. 2023 Sep 4:ljad318. doi: 10.1093.
    >> Share

  333. LLOYD-LAVERY A
    Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad319. doi: 10.1093.
    >> Share

  334. BANILA C, Green D, Katsanos D, Viana J, et al
    A non-invasive method for whole genome skin methylome profiling.
    Br J Dermatol. 2023 Sep 2:ljad316. doi: 10.1093.
    >> Share

  335. SUI JY, Eichenfield DZ, Sun BK
    The Role of Enhancers in Psoriasis and Atopic Dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad321. doi: 10.1093.
    >> Share

  336. LEE EY, Drucker AM
    A detailed evaluation of dupilumab's effect on sleep in adults with atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad320. doi: 10.1093.
    >> Share

  337. WEINER D, Ly A, Talluru S, Munjal A, et al
    Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
    Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093.
    >> Share

    August 2023
  338. HTET KZ, Griffiths CEM, Lwin SM
    Essential Emergency Skincare: A Global Health Dermatology Innovation for Myanmar and Beyond.
    Br J Dermatol. 2023 Aug 25:ljad302. doi: 10.1093.
    >> Share

  339. ELEFTHERIADOU V, Thompson AR
    Skin is a window to one's inner world.
    Br J Dermatol. 2023 Aug 25:ljad300. doi: 10.1093.
    >> Share


  340. Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.
    >> Share


  341. Validation of a blood test for melanoma.
    Br J Dermatol. 2023;189:e65.
    >> Share


  342. The impact of a dose reduction of dupilumab when treating people with well-controlled atopic dermatitis.
    Br J Dermatol. 2023;189:e68.
    >> Share


  343. Comparison of treatment for psoriasis with methotrexate and adalimumab.
    Br J Dermatol. 2023;189:e64.
    >> Share

  344. CLAESON M
    Real-world data show improved melanoma survival in Sweden.
    Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.
    >> Share


  345. Greater understanding about the impact of house dust mites in vitiligo.
    Br J Dermatol. 2023;189:e67.
    >> Share

  346. NG WHS, Smith SD
    New considerations and implications with weekly patient-reported symptom monitoring and eczema severity.
    Br J Dermatol. 2023;189:e58-e59.
    >> Share

  347. PICARDO M
    Vitiligo and keratinocytes or keratinocytes and vitiligo?
    Br J Dermatol. 2023;189:257.
    >> Share

  348. KEARNEY N, Kirby B
    Moving toward structured, specialized hidradenitis suppurativa care to improve patient outcomes.
    Br J Dermatol. 2023;189:e57-e58.
    >> Share

  349. ROESNER LM, Wittmann M
    Hand eczema leaves systemic traces.
    Br J Dermatol. 2023;189:e56-e59.
    >> Share

  350. MALOVITSKI K, Sarig O, Feller Y, Bergson S, et al
    Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma.
    Br J Dermatol. 2023;189:302-311.
    >> Share

  351. WILLIAMS JC, Alhusayen R, Guilbault S, Ingram JR, et al
    Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa.
    Br J Dermatol. 2023;189:351-353.
    >> Share

  352. LEIGHTON P, Howells L, Bates J, Gibbons A, et al
    Research priorities in the management of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:343-345.
    >> Share

  353. BELLEFEUILLE G, Paiewonsky B, Khalid B, Freese RL, et al
    Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity.
    Br J Dermatol. 2023;189:338-354.
    >> Share

  354. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
    Br J Dermatol. 2023;189:339-341.
    >> Share

  355. PHAM JP, Wark KJL, Woods J, Frew JW, et al
    Resident cutaneous memory T-cells: A clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets.
    Br J Dermatol. 2023 Aug 21:ljad303. doi: 10.1093.
    >> Share

  356. THOMAS SE, van den Reek JMPA, Seyger MMB, de Jong EMGJ, et al
    How to define a 'super-responder' to biologics in psoriasis studies?
    Br J Dermatol. 2023 Aug 18:ljad280. doi: 10.1093.
    >> Share

  357. SONG B, Wu C, Liu W, Wang Y, et al
    Integrative serum proteomics analysis reveals distinct immune and cardiovascular profiles dysregulation in erythrodermic psoriasis.
    Br J Dermatol. 2023 Aug 16:ljad283. doi: 10.1093.
    >> Share

  358. ARENTS BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, et al
    The future is now: the Global Atopic Dermatitis Atlas (GADA).
    Br J Dermatol. 2023 Aug 11:ljad286. doi: 10.1093.
    >> Share

  359. SMITH J, Cust AE, Lo SN
    Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
    Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
    >> Share

  360. MEROLA JF, Chiou AS, During E, Costanzo A, et al
    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study.
    Br J Dermatol. 2023 Aug 10:ljad284. doi: 10.1093.
    >> Share

  361. MIYAGAKI T, Inoue N, Kamijo H, Boki H, et al
    Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan.
    Br J Dermatol. 2023 Aug 4:ljad266. doi: 10.1093.
    >> Share

    July 2023
  362. IGARASHI A, Katsunuma T, Matsumura T, Komazaki H, et al
    Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
    Br J Dermatol. 2023 Jul 31:ljad268. doi: 10.1093.
    >> Share

  363. PAN CX, Kim DY, Lau CB, Lau WC, et al
    Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
    Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.
    >> Share

  364. CHULAROJANAMONTRI L, Panjapakkul W, Chaiyabutr C, Pruksaeakanan C, et al
    Blood-based Scoring Systems for Identifying Significant Liver Fibrosis in Psoriasis Patients.
    Br J Dermatol. 2023 Jul 28:ljad269. doi: 10.1093.
    >> Share

  365. STEIN GOLD LF, Bagel J, Tyring SK, Hong HC, et al
    Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study.
    Br J Dermatol. 2023 Jul 25:ljad252. doi: 10.1093.
    >> Share

  366. PILERI A, Pimpinelli N
    The role of the immune system in cutaneous T-cell lymphoma, an area requiring more investigation.
    Br J Dermatol. 2023 Jul 24:ljad255. doi: 10.1093.
    >> Share

  367. RINNOV MR, Gerner T, Halling AS, Liljendahl MS, et al
    The association between S. aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort.
    Br J Dermatol. 2023 Jul 22:ljad249. doi: 10.1093.
    >> Share

  368. MARCOMBES C, Penso L, Weill A, Dray-Spira R, et al
    Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Br J Dermatol. 2023 Jul 21:ljad248. doi: 10.1093.
    >> Share

  369. MICEVIC G, Daniels A, Flavell RA
    New insights into PD-1 blockade associated cutaneous immune-related adverse events.
    Br J Dermatol. 2023 Jul 20:ljad236. doi: 10.1093.
    >> Share

  370. THAI AA, Young RJ, Bressel M, Angel C, et al
    Comprehensive profiling identifies tumour and immune-microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma.
    Br J Dermatol. 2023 Jul 20:ljad250. doi: 10.1093.
    >> Share

  371. FAVARO R, Formai A, Pavia G, Gargiulo L, et al
    The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV2 infection and vaccination.
    Br J Dermatol. 2023 Jul 18:ljad242. doi: 10.1093.
    >> Share

  372. WEIDINGER S, Bieber T, Cork MJ, Reich A, et al
    Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial.
    Br J Dermatol. 2023 Jul 18:ljad240. doi: 10.1093.
    >> Share

  373. SMAK GREGOOR AM, van Egmond S, Nijsten TEC, Wakkee M, et al
    Time to reconsider skin cancer related follow-up visits.
    Br J Dermatol. 2023 Jul 18:ljad241. doi: 10.1093.
    >> Share

  374. VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
    Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
    Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
    >> Share


  375. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023;189:e39.
    >> Share


  376. The impact of weekly eczema symptom assessments on patient outcomes.
    Br J Dermatol. 2023;189:e38.
    >> Share


  377. Imsidolimab for the treatment of generalized pustular psoriasis.
    Br J Dermatol. 2023;189:e37.
    >> Share


  378. A review of genetic hair disorders.
    Br J Dermatol. 2023;189:e36.
    >> Share

  379. LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
    Comorbidities in palmoplantar pustulosis: a Swedish population-based register study.
    Br J Dermatol. 2023;189:230-232.
    >> Share

  380. BAKER A, Mitchell EJ, Partlett C, Thomas KS, et al
    Evaluating the effect of weekly patient-reported symptom monitoring on trial outcomes: results of the Eczema Monitoring Online randomized controlled trial.
    Br J Dermatol. 2023;189:180-187.
    >> Share

  381. MOGHADAM P, Tancrede E, Bouaziz JD, Kallout J, et al
    Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
    Br J Dermatol. 2023;189:244-246.
    >> Share

  382. SCHULTHEIS M, Staubach P, Nikolakis G, Schollenberger L, et al
    A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial.
    Br J Dermatol. 2023;189:170-179.
    >> Share

  383. YOTSU RR, Vagamon B, Almamy D, Aka N, et al
    Buruli ulcer: application of thermography for remote diagnosis of a neglected tropical disease.
    Br J Dermatol. 2023;189:236-238.
    >> Share

  384. CHORAGUDI S, Yosipovitch G
    Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States - National Inpatient Sample 2016-2019.
    Br J Dermatol. 2023;189:240-242.
    >> Share

  385. ASFOUR L, Bokhari L, Bhoyrul B, Eisman S, et al
    Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children.
    Br J Dermatol. 2023;189:248-250.
    >> Share

  386. SOKOLOFF A, Dykman M, Sokoloff G, Vellody K, et al
    If my hidradenitis had a voice, this is what it would say: the perspective of a young woman with Down syndrome and hidradenitis suppurativa.
    Br J Dermatol. 2023;189:221-222.
    >> Share

  387. MERHI S, Salameh P, Abboud M, Seneschal J, et al
    Facial involvement is reflective of patients' global perception of vitiligo extent.
    Br J Dermatol. 2023;189:188-194.
    >> Share

  388. KIRBY JS, Martorell A, Sayed CJ, Alarcon I, et al
    Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research.
    Br J Dermatol. 2023;189:228-230.
    >> Share

  389. ADAMSON SR, Higgins CL, Veysey E
    Hailey-Hailey disease (benign familial pemphigus) responsive to treatment with ocrelizumab for multiple sclerosis.
    Br J Dermatol. 2023;189:232-234.
    >> Share

  390. LAM M, Spuls PI, Leshem YA, Gerbens LAA, et al
    Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis.
    Br J Dermatol. 2023 Jul 12:ljad237. doi: 10.1093.
    >> Share

  391. KEARNEY N, Kirby B
    The expanding psoriasis therapeutic landscape - reading and understanding clinical trials.
    Br J Dermatol. 2023 Jul 12:ljad238. doi: 10.1093.
    >> Share

  392. CHIU YM, Chiu HY
    Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019.
    Br J Dermatol. 2023 Jul 10:ljad234. doi: 10.1093.
    >> Share

  393. THOMAS SE, van den Reek JMPA
    Should we prefer biologics over non-biologic agents in psoriasis?
    Br J Dermatol. 2023 Jul 9:ljad231. doi: 10.1093.
    >> Share


  394. Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults.
    Br J Dermatol. 2023;189:e31.
    >> Share


  395. Safety of treatment with guselkumab in clinical trials for up to 5 years in patients with moderate-to-severe plaque psoriasis.
    Br J Dermatol. 2023;189:e29.
    >> Share


  396. An oncogene-targeted therapy for Merkel cell carcinoma.
    Br J Dermatol. 2023;189:e33.
    >> Share


  397. The use of biosimilars for psoriasis in the UK and Ireland.
    Br J Dermatol. 2023;189:e30.
    >> Share


  398. Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023;189:e34.
    >> Share


  399. Finding treatments to reduce scaling in ichthyosis.
    Br J Dermatol. 2023;189:e32.
    >> Share

  400. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    >> Share


  401. Review of treatments for toenail onychomycosis caused by dermatophytes.
    Br J Dermatol. 2023;189:e28.
    >> Share

  402. GORBATENKO-ROTH K, Wood S, Johnson M, Wallander I, et al
    Beyond health-related quality of life: initial psychometric validation of a new scale for addressing the gap in assessing the full range of alopecia areata psychosocial burden.
    Br J Dermatol. 2023;189:71-79.
    >> Share

  403. GUPTA AK, Venkataraman M, Bamimore MA
    Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study.
    Br J Dermatol. 2023;189:12-22.
    >> Share

  404. LLOYD-LAVERY A
    Further evidence for the long-term safety of guselkumab.
    Br J Dermatol. 2023;189:10-11.
    >> Share

  405. ITO T, Kageyama R
    Is the Scale of Alopecia Areata Distress a new method of assessing the psychological burden of alopecia areata?
    Br J Dermatol. 2023;189:8.
    >> Share

  406. KERVARREC T
    From genetic characterization to new potential therapeutic options: targeting Bcl-xL in Merkel carcinoma.
    Br J Dermatol. 2023;189:7.
    >> Share

  407. ZIEGLER A, Ebstein F, Shamseldin H, Prouteau C, et al
    Gain-of-function variants in the KDF1 gene cause hidradenitis suppurativa associated with ectodermal dysplasia by stabilizing IkappaB kinase alpha.
    Br J Dermatol. 2023;189:131-132.
    >> Share

  408. HENNIES HC
    Does the understanding of signalling pathways pave the way to therapies for keratinization disorders?
    Br J Dermatol. 2023;189:5-6.
    >> Share

  409. KORTE EWH, Welponer T, Kottner J, van der Werf S, et al
    Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization.
    Br J Dermatol. 2023;189:80-90.
    >> Share

  410. PETROF G, Martinez AE
    Epidermolysis bullosa: time to come together for better outcomes.
    Br J Dermatol. 2023;189:5.
    >> Share

  411. BURGESS IF, Brunton ER
    Head lice: evidence that resistance to physically acting treatments is developing.
    Br J Dermatol. 2023;189:144-145.
    >> Share

  412. CONNOLLY A, Walsh S, Philippidou M, Salisbury J, et al
    Acute hepatic failure in trimethoprim-induced drug rash with eosinophilia and systemic symptoms (DRESS).
    Br J Dermatol. 2023;189:140-141.
    >> Share

  413. CROWDER D, Herbert S, Haughton R
    Psychosocial impact of pyoderma gangrenosum: a patient perspective.
    Br J Dermatol. 2023;189:125-128.
    >> Share

  414. WARREN RB, Basey V, Lynam A, Curtis C, et al
    The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care.
    Br J Dermatol. 2023 Jul 7:ljad212. doi: 10.1093.
    >> Share

  415. YEN H, Chiu YE
    More than skin deep: Getting on the same page for mental health in children and young people with skin conditions.
    Br J Dermatol. 2023 Jul 7:ljad232. doi: 10.1093.
    >> Share

  416. KWIATKOWSKA D, Reich A
    Seeking new topical therapies in psoriasis.
    Br J Dermatol. 2023 Jul 7:ljad233. doi: 10.1093.
    >> Share

  417. ERTUS C, Scailteux LM, Lescoat A, Berthe P, et al
    Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093.
    >> Share

  418. GOLLINS CE, Coates LC
    Validation of a new measure of patient global assessment in psoriasis.
    Br J Dermatol. 2023 Jul 6:ljad228. doi: 10.1093.
    >> Share

  419. TSAI YC, Schlaepfer T, Ignatova D, Chang YT, et al
    Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.
    Br J Dermatol. 2023 Jul 6:ljad220. doi: 10.1093.
    >> Share

  420. GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
    Nevus count on the face for the identification of patients with higher risk of melanoma.
    Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.
    >> Share

  421. OLLECH A, Lefferdink R, Sheth A, Blumstein A, et al
    Systemic Immunosuppressive Therapies for Children with Refractory Atopic Dermatitis: A Large Real-Life Cohort Study.
    Br J Dermatol. 2023 Jul 5:ljad222. doi: 10.1093.
    >> Share

  422. HONG CH, Lee CH
    A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism.
    Br J Dermatol. 2023 Jul 5:ljad221. doi: 10.1093.
    >> Share

  423. JUNEJO MH, Wolfe I, Patel J, Duus E, et al
    Use of the Dermatology Life Quality Index suite of patient reported outcome measures in skin neglected tropical diseases.
    Br J Dermatol. 2023 Jul 3:ljad217. doi: 10.1093.
    >> Share

  424. RIBERO S, Quaglino P, Roccuzzo G
    Predicting progression in very thin melanoma: the challenge of the next decade?
    Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.
    >> Share

    June 2023
  425. TSAI TF
    Heterogeneity of generalized pustular psoriasis in multi-ethnic Johor Bahru, Malaysia.
    Br J Dermatol. 2023 Jun 28:ljad197. doi: 10.1093.
    >> Share

  426. BARRABES-TORRELLA C, Arandes-Marcocci J, Armillas-Lliteras L, Posada-Caez RA, et al
    Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors.
    Br J Dermatol. 2023 Jun 28:ljad206. doi: 10.1093.
    >> Share

  427. LUO M, Zhu C, Lin J, Lin L, et al
    Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19.
    Br J Dermatol. 2023 Jun 27:ljad208. doi: 10.1093.
    >> Share

  428. OGAWA-MOMOHARA M, Muro Y, Murase C, Taki T, et al
    Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.
    Br J Dermatol. 2023 Jun 27:ljad207. doi: 10.1093.
    >> Share

  429. HAN JH, Ju HJ, Kang H, Lee JH, et al
    Autoimmune, Inflammatory, Allergic, and Neuropsychiatric Outcomes of Offspring Born to Mothers with Vitiligo: A Nationwide Population-based Birth Cohort Study of Korea.
    Br J Dermatol. 2023 Jun 19:ljad196. doi: 10.1093.
    >> Share

  430. YU N, Peng C, Zhou J, Gu J, et al
    Measurement properties of the Patient Global Assessment numerical rating scale in moderate-to-severe psoriasis.
    Br J Dermatol. 2023 Jun 13:ljad188. doi: 10.1093.
    >> Share

  431. MCPHERSON T, Ravenscroft J, Ali R, Barlow R, et al
    British Society for Paediatric and Adolescent Dermatology (BSPAD) assessment and support of mental health in children and young people (CYP) with skin conditions: A multi-disciplinary expert consensus statement and recommendations.
    Br J Dermatol. 2023 Jun 9:ljad193. doi: 10.1093.
    >> Share

  432. KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
    Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
    Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
    >> Share

  433. AKIYAMA M
    Cathepsin and cutaneous disorders of cornification and inflammation: Their close links.
    Br J Dermatol. 2023 Jun 8:ljad190. doi: 10.1093.
    >> Share

  434. LAX SJ, Roberts A, Cliffe E, Ramesh G, et al
    Public views are needed for skin colour scales.
    Br J Dermatol. 2023 Jun 8:ljad189. doi: 10.1093.
    >> Share

  435. AGUILAR-CALDERON PE, Reyes-Soto MA, Sanchez-Meza E, Brown-Herrera A, et al
    Melanonychia as a manifestation of chronic lead poisoning.
    Br J Dermatol. 2023 Jun 7:ljad194. doi: 10.1093.
    >> Share

  436. KIRCIK LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, et al
    Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase 2b study.
    Br J Dermatol. 2023 Jun 5:ljad182. doi: 10.1093.
    >> Share

  437. VERGARA IA, Stark MS
    One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
    Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.
    >> Share

    May 2023
  438. MORAN B, Smith CM, Zabarowski A, Ryan M, et al
    Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin.
    Br J Dermatol. 2023 May 27:ljad184. doi: 10.1093.
    >> Share

  439. MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
    Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
    Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.
    >> Share

  440. LAWSON A, Wininger M, Wang M, Steger M, et al
    Premenarchal Lichen Sclerosus: A Multicenter Examination of the Novel Diagnostic Tool, the SWIFT Model.
    Br J Dermatol. 2023 May 26:ljad180. doi: 10.1093.
    >> Share

  441. ALABAS OA, Mason KJ, Yiu ZZN, Warren RB, et al
    Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Br J Dermatol. 2023 May 25:ljad179. doi: 10.1093.
    >> Share


  442. Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
    Br J Dermatol. 2023;188:e43.
    >> Share


  443. Skin cancer incidence and survival rates in England, 2013-2019.
    Br J Dermatol. 2023;188:e45.
    >> Share


  444. Atopic eczema: palmar patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:e46.
    >> Share


  445. Atopic dermatitis across the globe: differences in prevalence and access to treatments.
    Br J Dermatol. 2023;188:e42.
    >> Share

  446. PANDYA R, Kleitsch J, Werth VP
    Trial of intravenous immunoglobulin in dermatomyositis: a critically appraised research paper.
    Br J Dermatol. 2023;188:738-739.
    >> Share

  447. GARG A, Rawal S, Akilov O, Alavi A, et al
    Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project.
    Br J Dermatol. 2023;188:808-810.
    >> Share

  448. ALONSO-ALONSO R, Rodriguez M, Garcia-Diaz N, Tomas-Roca L, et al
    NanoString analysis of mycosis fungoides reveals individual molecular identity.
    Br J Dermatol. 2023;188:812-814.
    >> Share

  449. O'CONNELL KA, Schaefer M, Atzmony L, Vleugels RA, et al
    Clinical features in adults with acquired cutis laxa: a retrospective review.
    Br J Dermatol. 2023;188:800-816.
    >> Share

  450. THOMAS BR, Tan XL, Van Duijvenboden S, Hogan SC, et al
    Deep palmar phenotyping in atopic eczema: patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:785-792.
    >> Share

  451. CHOSIDOW O, Chang AY
    The skin of people experiencing homelessness: more (known) is less (neglected).
    Br J Dermatol. 2023;188:694-695.
    >> Share


  452. Two melanoma genes (MITF and MC1R) interact to cause different risks.
    Br J Dermatol. 2023;188:e44.
    >> Share

  453. BECHMAN K, Hayes JF, Mathewman J, Henderson A, et al
    Electronic screening for mental illness in patients with psoriasis.
    Br J Dermatol. 2023 May 24:ljad141. doi: 10.1093.
    >> Share

  454. HIJNEN D, Olydam J
    Prediction of response to dupilumab treatment.
    Br J Dermatol. 2023;188:e41.
    >> Share

  455. POGORZELSKA-DYRBUS J, Szepietowski JC
    Melanoma cells in optical super-high magnification dermoscopy.
    Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.
    >> Share


  456. Correction to: 319 Effects of omega-3 fatty acid supplementation on atopic dermatitis.
    Br J Dermatol. 2023 May 22:ljad154. doi: 10.1093.
    >> Share

  457. TAKEICHI T, Ito Y, Lee JYW, Murase C, et al
    KLK11 ichthyosis: large truncal hyperkeratotic pigmented plaques underscore a distinct autosomal dominant disorder of cornification.
    Br J Dermatol. 2023 May 22:ljad082. doi: 10.1093.
    >> Share

  458. VROOM IR, Hulshof MA, Schelhaas W, Koning SN, et al
    Differences and similarities in teledermatological primary care case histories between people with skin of color and White skin.
    Br J Dermatol. 2023 May 20:ljad164. doi: 10.1093.
    >> Share

  459. ROMITI R, Martins LPF, Santana YRT, Timbo RV, et al
    Prevalence of psoriasis and other autoimmune skin diseases in a recently contacted Amerindian community in the Auaris region, Yanomami territory, Brazil.
    Br J Dermatol. 2023 May 20:ljad165. doi: 10.1093.
    >> Share

  460. SPEKHORST LS, Boesjes CM, Loman L, Zuithoff NPA, et al
    Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Br J Dermatol. 2023 May 13:ljad159. doi: 10.1093.
    >> Share

  461. PETERKNECHT E, Scarisbrick J
    Skin Swabs in the Skin Lymphoma Clinic - From Swab to Treatment.
    Br J Dermatol. 2023 May 13:ljad160. doi: 10.1093.
    >> Share

  462. CHOON SE, Wright AK, Griffiths CEM, Wong KW, et al
    Incidence and prevalence of generalised pustular psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in Teleprimary Care (TPC(R)) clinical information system from 2010 to
    Br J Dermatol. 2023 May 10:ljad158. doi: 10.1093.
    >> Share

  463. CRANWELL WC, Sinclair RD
    Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?
    Br J Dermatol. 2023 May 8:ljad157. doi: 10.1093.
    >> Share

  464. DAN J, Sprow G, Concha J, Patel J, et al
    A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis.
    Br J Dermatol. 2023 May 5:ljad133. doi: 10.1093.
    >> Share

  465. VAN LAAR R, Latif B, King S, Love C, et al
    Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
    Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
    >> Share

  466. BZIOUECHE H, Boniface K, Drullion C, Marchetti S, et al
    Impact of House-Dust-Mite in Vitiligo Skin: Environmental Contribution to Increased Cutaneous Immunity and Melanocyte Detachment.
    Br J Dermatol. 2023 May 4:ljad148. doi: 10.1093.
    >> Share

  467. FREEMAN EE, Garcia-Doval I, Naldi L, Hay RJ, et al
    COVID-19 and the skin, three years on: long term impacts, emerging trends and clinical practice.
    Br J Dermatol. 2023 May 3:ljad131. doi: 10.1093.
    >> Share

  468. PATRA S, Karat TP, Kaur M
    Buried dermal interrupted or vertical mattress: what to prefer for dermal layer suturing of surgical skin wounds?
    Br J Dermatol. 2023 May 3:ljad132. doi: 10.1093.
    >> Share


  469. Correction to: Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 May 2:ljad130. doi: 10.1093.
    >> Share

    April 2023
  470. FLOHR C, Irvine AD, Cork MJ, Simpson EL, et al
    Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 30:ljad124. doi: 10.1093.
    >> Share

  471. WARREN RB, Reich A, Kaszuba A, Placek W, et al
    Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial.
    Br J Dermatol. 2023 Apr 30:ljad083. doi: 10.1093.
    >> Share

  472. ARENTS BWM
    Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 24:ljad068. doi: 10.1093.
    >> Share

  473. BAO C, Xu Q, Xiao Z, Wang H, et al
    Abrocitinib as a novel treatment for lichen sclerosus.
    Br J Dermatol. 2023 Apr 24:ljad129. doi: 10.1093.
    >> Share

  474. GLEESON D, Mahil SK
    Imsidolimab: an emerging biologic therapy for generalised pustular psoriasis.
    Br J Dermatol. 2023 Apr 20:ljad128. doi: 10.1093.
    >> Share


  475. Immunity 6 months after COVID-19 vaccination in patients with psoriasis treated with immunomodulatory drugs.
    Br J Dermatol. 2023;188:e38.
    >> Share


  476. Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
    Br J Dermatol. 2023;188:e37.
    >> Share


  477. The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
    Br J Dermatol. 2023;188:e35.
    >> Share


  478. Neutrophil migration in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:e36.
    >> Share

  479. WOLK K
    Hope for a new therapy for hidradenitis suppurativa: blocking of granulocyte colony-stimulating factor receptor.
    Br J Dermatol. 2023;188:590.
    >> Share

  480. DUDINK K, Bouwman K, Chen Y, DePrimo SE, et al
    Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
    Br J Dermatol. 2023;188:601-609.
    >> Share

  481. STARRETT GJ, Lee JW, Chatterjee S, Jedrych JJ, et al
    Detection of extensive host-virus DNA hybrids in human polyomavirus 7-associated pruritic rash.
    Br J Dermatol. 2023;188:675-677.
    >> Share

  482. MENDES-BASTOS P, Martorell A, Bettoli V, Matos AP, et al
    The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review.
    Br J Dermatol. 2023;188:591-600.
    >> Share

  483. WARK KJL, Der Sarkissian SA, Tatian A, Woods J, et al
    The association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis.
    Br J Dermatol. 2023;188:673-675.
    >> Share

  484. SCHUSTER B, Gallinger J, Philipp-Dormston WG, Vasel M, et al
    Less confident, successful and happy: patients with post-acne hyperpigmentation are stigmatized.
    Br J Dermatol. 2023;188:682-684.
    >> Share

  485. FREW JW
    In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:588-589.
    >> Share

  486. SANTOS LL, Zhu Z, Brown K, Kirby JS, et al
    Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial setting.
    Br J Dermatol. 2023;188:672-673.
    >> Share

  487. GAMELL C, Bankovacki A, Scalzo-Inguanti K, Sedgmen B, et al
    CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:636-648.
    >> Share

  488. VALENTI M, Costanzo A
    Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation.
    Br J Dermatol. 2023;188:586-590.
    >> Share

  489. BURDEN AD, Bachelez H, Choon SE, Marrakchi S, et al
    The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
    Br J Dermatol. 2023 Apr 19:ljad071. doi: 10.1093.
    >> Share

  490. BEN ABDALLAH H, Johansen C
    Transmembrane protein 232 (TMEM232) regulates inflammation in experimental models of atopic dermatitis.
    Br J Dermatol. 2023 Apr 17:ljad127. doi: 10.1093.
    >> Share

  491. TAKEICHI T, Muro Y, Akiyama M
    Ichthyotic skin phenotype induced by the chronic activation of Toll-like receptor 2, and autoinflammation.
    Br J Dermatol. 2023 Apr 17:ljad122. doi: 10.1093.
    >> Share

  492. LALLAS A
    Which melanoma patients are at priority for monitoring to detect new primary melanoma?
    Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.
    >> Share

  493. SBIDIAN E
    A multistep approach from scoping review to strong evidence: biomarkers in psoriasis.
    Br J Dermatol. 2023 Apr 13:ljac101. doi: 10.1093.
    >> Share

  494. QUAADE AS, Wang X, Solberg JBK, Ulrich NH, et al
    Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023 Apr 13:ljad110. doi: 10.1093.
    >> Share

  495. DESCATHA A, Ezzedine K, Le Roux G
    A case of Paederus Dermatitis in Western Europe: a signal for One Health -One World concept for the dermatologist.
    Br J Dermatol. 2023 Apr 13:ljad103. doi: 10.1093.
    >> Share

  496. KELLY L, Coote L, Dinnes J, Fleming C, et al
    Key issues when considering adopting a skin cancer diagnostic tool which uses artificial intelligence.
    Br J Dermatol. 2023 Apr 12:ljad080. doi: 10.1093.
    >> Share

  497. VITTRUP I
    Malignancy risk in atopic dermatitis: heterogenous effects and perspectives.
    Br J Dermatol. 2023 Apr 11:ljad119. doi: 10.1093.
    >> Share

  498. IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
    Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
    Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.
    >> Share

  499. GRIFFIN L, O'Reilly P, Murphy M, Prendergast G, et al
    Photoprotection and Skin Cancer Education - the Experiences of Renal Transplant Recipients, a qualitative study. Why the 'personal touch' is important.
    Br J Dermatol. 2023 Apr 6:ljad116. doi: 10.1093.
    >> Share

  500. LEBWOHL MG, Merola JF, Rowland K, Miller M, et al
    Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure.
    Br J Dermatol. 2023 Apr 6:ljad115. doi: 10.1093.
    >> Share

  501. FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
    Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
    Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.
    >> Share

  502. PHAN DB, Bewley AP, Smith CH, Mackenzie T, et al
    Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Br J Dermatol. 2023 Apr 5:ljad107. doi: 10.1093.
    >> Share

  503. SPELMAN L
    Safety and longevity of biologic treatment in the setting of moderate to severe psoriasis - enhancing the body of evidence.
    Br J Dermatol. 2023 Apr 3:ljad112. doi: 10.1093.
    >> Share

  504. GUNTHER C
    Rapid response of cutaneous lupus erythematosus to treatment with the type I interferon receptor antagonist anifrolumab.
    Br J Dermatol. 2023 Apr 1:ljad111. doi: 10.1093.
    >> Share

    March 2023
  505. TORRELO A, Rewerska B, Galimberti M, Paller A, et al
    Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, place
    Br J Dermatol. 2023 Mar 31:ljad096. doi: 10.1093.
    >> Share


  506. Factors associated with mental illness in adults with atopic eczema or psoriasis.
    Br J Dermatol. 2023;188:e27.
    >> Share


  507. Quality of life of Bangladeshi children and young adults with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:e33.
    >> Share


  508. Parent and child experiences of skin conditions and views on mindfulness-based support.
    Br J Dermatol. 2023;188:e32.
    >> Share


  509. Effects of air pollution on psoriasis in Wuhan, China.
    Br J Dermatol. 2023;188:e30.
    >> Share


  510. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
    Br J Dermatol. 2023;188:e29.
    >> Share


  511. What do parents/carers of children with eczema and young people with eczema think of two websites to help them to manage eczema?
    Br J Dermatol. 2023;188:e31.
    >> Share

  512. KRIDIN K, Mruwat N, Amber KT, Ludwig RJ, et al
    Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study.
    Br J Dermatol. 2023;188:499-505.
    >> Share

  513. BOZONNAT A, Polivka L, Leclerc-Mercier S, Luscan R, et al
    Severe tracheal involvement in type XVII collagen junctional epidermolysis bullosa.
    Br J Dermatol. 2023;188:564-566.
    >> Share

  514. DRUMM C, Chawla S, Kravvas G, Spencer A, et al
    Representation of genital dermatoses in dermatological literature.
    Br J Dermatol. 2023;188:563-564.
    >> Share

  515. PIMENTEL MA, Li MM, Noe MH, Latour E, et al
    Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.
    Br J Dermatol. 2023;188:566-568.
    >> Share

  516. GREENWELL K, Sivyer K, Howells L, Steele M, et al
    'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema.
    Br J Dermatol. 2023;188:506-513.
    >> Share

  517. TAWFIK SS, Thomas BR, Kelsell DP, Grigg J, et al
    Dermatology Quality of Life Index scores in Bangladeshi patients with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:524-532.
    >> Share

  518. STEYN M, Ayis S, O'Connor J, Lakhan MK, et al
    Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting.
    Br J Dermatol. 2023;188:573-574.
    >> Share

  519. CAZZANIGA S, Naldi L, Borradori L
    Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study.
    Br J Dermatol. 2023;188:454-455.
    >> Share

  520. MAGIN P, Fisher K
    Online behavioural interventions for children and young people with atopic eczema: refining the way forward.
    Br J Dermatol. 2023;188:453.
    >> Share

  521. GLEESON D, Barker JNWN, Capon F, Pink AE, et al
    Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic.
    Br J Dermatol. 2023;188:471-473.
    >> Share

  522. JIANG SW, Petty AJ, Jacobs JL, Robinson C, et al
    Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa.
    Br J Dermatol. 2023;188:555-576.
    >> Share

  523. BELZER A, Leasure AC, Damsky W, Cohen JM, et al
    The association of anxiety with granuloma annulare: a case-control study of the National Institutes of Health 'All of Us' research programme.
    Br J Dermatol. 2023;188:558-560.
    >> Share

  524. VANCE TM, Li T, Cho E, Drucker AM, et al
    Prenatal antibiotic use and subsequent risk of atopic eczema.
    Br J Dermatol. 2023;188:561-563.
    >> Share

  525. CAPOZZA K
    Lost in translation: understanding the experience of atopic eczema among non-English-speaking families.
    Br J Dermatol. 2023;188:456-457.
    >> Share

  526. DIFFEY BL
    Sun protection: false beliefs and misguided advocacy.
    Br J Dermatol. 2023;188:552-554.
    >> Share

  527. BLAUVELT A, Thyssen JP, Guttman-Yassky E, Bieber T, et al
    Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Br J Dermatol. 2023 Mar 30:ljad022. doi: 10.1093.
    >> Share


  528. Potential new solution to reduce skin complications and improve quality of life in people living with a stoma.
    Br J Dermatol. 2023;188:e28.
    >> Share

  529. ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
    The geographical variation of melanoma, basal and squamous cell carcinoma in England.
    Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.
    >> Share

  530. FAN K, Srinivas N, Kubat L, Gravemeyer J, et al
    B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.
    Br J Dermatol. 2023 Mar 30:ljad099. doi: 10.1093.
    >> Share

  531. DOOLAN BJ, Rayinda T, Chiu FP, McGrath JA, et al
    A review of genotrichoses and hair pathology associated with inherited skin diseases.
    Br J Dermatol. 2023 Mar 29:ljad102. doi: 10.1093.
    >> Share

  532. BRUNO W
    Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
    Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.
    >> Share

  533. TAGOE H, Hassan S, Youssef G, Heywood W, et al
    Chronic activation of Toll-like receptor 2 induces an ichthyotic skin phenotype.
    Br J Dermatol. 2023 Mar 27:ljad095. doi: 10.1093.
    >> Share

  534. LANDIS MN, Smith SR, Berstein G, Fetterly G, et al
    Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study.
    Br J Dermatol. 2023 Mar 27:ljad098. doi: 10.1093.
    >> Share

  535. STROBER B, Tada Y, Mrowietz U, Lebwohl M, et al
    Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
    Br J Dermatol. 2023 Mar 27:ljad035. doi: 10.1093.
    >> Share

  536. NI Y, Watts CG, Scolyer RA, Madronio C, et al
    Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
    Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.
    >> Share

  537. SINIKUMPU SP, Jokelainen J, Huilaja L
    The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study.
    Br J Dermatol. 2023 Mar 22:ljad086. doi: 10.1093.
    >> Share

  538. RAGAMIN A, Tupker RA, de Graaf M, Rustemeyer T, et al
    Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
    Br J Dermatol. 2023 Mar 22:ljad085. doi: 10.1093.
    >> Share

  539. CARTER LM, Wigston Z, Laws P, Vital EM, et al
    Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
    Br J Dermatol. 2023 Mar 22:ljad089. doi: 10.1093.
    >> Share

  540. BLAUVELT A, Thaci D, Papp KA, Ho V, et al
    Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
    Br J Dermatol. 2023 Mar 22:ljad081. doi: 10.1093.
    >> Share

  541. PATHMARAJAH P, Corso R, Salam A, Shah G, et al
    Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
    Br J Dermatol. 2023 Mar 17:ljad038. doi: 10.1093.
    >> Share

  542. HAN J, Cai X, Qin S, Zhang Z, et al
    TMEM232 Promotes the Inflammatory Response in Atopic Dermatitis via NF-kappaB and STAT3 Signaling Pathways.
    Br J Dermatol. 2023 Mar 17:ljad078. doi: 10.1093.
    >> Share

  543. SINGH N, Schikowski T
    Skin diseases and emerging determinants: the need for interactive research.
    Br J Dermatol. 2023 Mar 14:ljad008. doi: 10.1093.
    >> Share

  544. DE VRIES E
    The important but difficult exercise of getting valid descriptive skin cancer data.
    Br J Dermatol. 2023 Mar 10:ljad065. doi: 10.1093.
    >> Share

  545. DRAELOS ZD, Adam DN, Hong CH, Lebwohl MG, et al
    Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
    Br J Dermatol. 2023 Mar 9:ljad060. doi: 10.1093.
    >> Share

  546. MOSAM A, Todd G
    Global epidemiology and disparities in atopic dermatitis.
    Br J Dermatol. 2023 Mar 7:ljad042. doi: 10.1093.
    >> Share

  547. WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
    MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
    Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
    >> Share

  548. DE DIOS MA, Arroyo-Andres J, Rubio-Muniz C, Concepcion Garrido M, et al
    Cutaneous features at injection sites of intravenous mephedrone.
    Br J Dermatol. 2023 Mar 5:ljad064. doi: 10.1093.
    >> Share

  549. OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
    The ethical implications of opportunistic detection of melanoma in clinical care.
    Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.
    >> Share

  550. GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
    Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
    Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.
    >> Share

  551. DRUCKER AM
    Atopic dermatitis in 2023 and beyond.
    Br J Dermatol. 2023 Mar 2:ljad053. doi: 10.1093.
    >> Share

    February 2023
  552. VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
    "Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
    Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
    >> Share


  553. Greater understanding about other diseases that are closely linked to having a diagnosis of psoriasis.
    Br J Dermatol. 2023;188:e23.
    >> Share


  554. Atopic dermatitis and school performance in children and young adults.
    Br J Dermatol. 2023;188:e21.
    >> Share


  555. New findings about what drives inflammation in hidradenitis suppurativa may lead to new treatments.
    Br J Dermatol. 2023;188:e24.
    >> Share


  556. Skin cancer and ultraviolet-radiation exposure in different jobs.
    Br J Dermatol. 2023;188:e22.
    >> Share

  557. JAYASINGHE D, Koh U, Plasmeijer EI, Menzies SW, et al
    The dynamic nature of naevi in adulthood: prospective population-based study using three-dimensional total-body photography.
    Br J Dermatol. 2023;188:437-439.
    >> Share

  558. FAN B, Wang M
    Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases.
    Br J Dermatol. 2023;188:432-434.
    >> Share

  559. NILSSON SF, Ali Z, Laursen TM, Thyssen JP, et al
    Association of homelessness and skin conditions: A Danish population-based cohort study.
    Br J Dermatol. 2023 Feb 22:ljad040. doi: 10.1093.
    >> Share

  560. VALENTI M, Costanzo A
    Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials.
    Br J Dermatol. 2023;188:316-317.
    >> Share

  561. EADIE E, Josso M, Touti R, Renoux P, et al
    Commercial visible-light protecting sunscreens for photosensitive individuals.
    Br J Dermatol. 2023;188:445-447.
    >> Share

  562. SUN X, Sheng A, Xu AE
    Successful treatment of vitiligo with crisaborole ointment: a report of two cases.
    Br J Dermatol. 2023;188:436-437.
    >> Share

  563. LI HO, Bailey AMJ, Pastukhova E, Tan MG, et al
    Comorbid diagnosis of systemic lupus erythematosus in vitiligo: a systematic review and meta-analysis.
    Br J Dermatol. 2023;188:440-441.
    >> Share

  564. FAGAN N, Doherty GA, Meah N, Sinclair R, et al
    Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata.
    Br J Dermatol. 2023;188:442-443.
    >> Share

  565. BHATE K, Mansfield KE, Sinnott SJ, Margolis DJ, et al
    Long-term oral antibiotic use in people with acne vulgaris in UK primary care: a drug utilization study.
    Br J Dermatol. 2023;188:361-371.
    >> Share

  566. GIAMARELLOS-BOURBOULIS EJ
    Keratinocytes as drivers of hidradenitis suppurativa inflammation: need for priming.
    Br J Dermatol. 2023;188:318-319.
    >> Share

  567. KRAJEWSKI PK, Matusiak L, Szepietowski JC
    Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review.
    Br J Dermatol. 2023;188:320-327.
    >> Share

  568. AGARWALA S, Mata DA, Safeer LZ, Hafeez F, et al
    Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern.
    Br J Dermatol. 2023;188:439-440.
    >> Share

  569. COLLINS MS, Ali S, Wiss IP, Senna MM, et al
    Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss.
    Br J Dermatol. 2023;188:429-447.
    >> Share

  570. SMITH H, Hussain W
    Is it time we changed the way we manage melanoma in situ of the trunk and limbs?
    Br J Dermatol. 2023 Feb 18:ljad031. doi: 10.1093.
    >> Share

  571. VON KOBYLETZKI L
    Which patients with atopic eczema and psoriasis develop depression, anxiety, and severe mental illness: is the evidence clear?
    Br J Dermatol. 2023 Feb 15:ljad009. doi: 10.1093.
    >> Share

  572. OLSEN CM, Pandeya N, Whiteman DC
    The rise in thick melanomas: can early detection reduce the burden?
    Br J Dermatol. 2023 Feb 15:ljad034. doi: 10.1093.
    >> Share

  573. PUIG L
    Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination.
    Br J Dermatol. 2023;188:163-165.
    >> Share


  574. Responses to AstraZeneca COVID-19 vaccines in patients with immune-mediated skin diseases.
    Br J Dermatol. 2023;188:e19.
    >> Share


  575. Photodamage and photoprotection in populations with skin of colour.
    Br J Dermatol. 2023;188:e11.
    >> Share


  576. Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease.
    Br J Dermatol. 2023;188:e18.
    >> Share


  577. A review of the role of four types of epidermal cells in messaging between the skin, nervous system and immune system.
    Br J Dermatol. 2023;188:e12.
    >> Share


  578. Patients successfully treated with baricitinib for atopic dermatitis: what happens if they lower their dose or stop treatment?
    Br J Dermatol. 2023;188:e14.
    >> Share

  579. REICH K, Simpson E, Wollenberg A, Bissonnette R, et al
    Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Br J Dermatol. 2023;188:208-217.
    >> Share

  580. KRUTMANN J, Piquero-Casals J, Morgado-Carrasco D, Granger C, et al
    Photoprotection for people with skin of colour: needs and strategies.
    Br J Dermatol. 2023;188:168-175.
    >> Share

  581. TALAGAS M
    Anatomical contacts between sensory neurons and epidermal cells: an unrecognized anatomical network for neuro-immuno-cutaneous crosstalk.
    Br J Dermatol. 2023;188:176-185.
    >> Share

  582. SHARMA A, Birnie AJ, Bordea C, Cheung ST, et al
    British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022.
    Br J Dermatol. 2023;188:186-194.
    >> Share

  583. KHAN SS, Ashcroft DM, Dlova N, Kini LC, et al
    A skin disease survey of the Maasai in North Eastern Tanzania.
    Br J Dermatol. 2023;188:303-304.
    >> Share

  584. ZAGONA-PRIZIO C, Khan S, Yee DK, Khan S, et al
    Psoriasis and fatigue: a cross-sectional population study of psoriasis patients in the United States using the Medical Expenditure Panel Surveys.
    Br J Dermatol. 2023;188:301-303.
    >> Share

  585. YANG DD, Borsky K, Jani C, Crowley C, et al
    Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017.
    Br J Dermatol. 2023;188:237-246.
    >> Share

  586. ADAMS L, Nakafero G, Grainge MJ, Card T, et al
    Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum).
    Br J Dermatol. 2023;188:297-299.
    >> Share

  587. LANGLEY RG, Sofen H, Dei-Cas I, Reich K, et al
    Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
    Br J Dermatol. 2023;188:198-207.
    >> Share

  588. GILL K, Xu J, Kozera E, Stewart T, et al
    Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility.
    Br J Dermatol. 2023;188:294-295.
    >> Share

  589. CARRASCOSA JM
    Conventional therapy in psoriasis. Lost in translation?
    Br J Dermatol. 2023 Feb 10:ljad030. doi: 10.1093.
    >> Share

  590. POIZEAU F, Balusson F, Lemaitre F, Tron C, et al
    The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
    Br J Dermatol. 2023 Feb 10:ljac085. doi: 10.1093.
    >> Share

  591. COWDELL F
    Living with hidradenitis suppurativa: managing the pain.
    Br J Dermatol. 2023;188:e10.
    >> Share


  592. Safety of baricitinib in adults with severe alopecia areata.
    Br J Dermatol. 2023;188:e15.
    >> Share


  593. Guidelines from the British Association of Dermatologists for the management of people with squamous cell carcinoma in situ (Bowen disease).
    Br J Dermatol. 2023;188:e13.
    >> Share


  594. Small particles of cobalt cause eczema in people with allergies.
    Br J Dermatol. 2023;188:e20.
    >> Share


  595. Merkel cell carcinoma: changes in the number of people affected, treatment and survival between 2004 and 2018.
    Br J Dermatol. 2023;188:e16.
    >> Share


  596. A review of the outcome measures used in clinical trials for vitiligo.
    Br J Dermatol. 2023;188:e17.
    >> Share

  597. MISTRY K, Levell NJ, Hollestein L, Wakkee M, et al
    Trends in incidence, treatment and survival of Merkel cell carcinoma in England 2004-2018: a cohort study.
    Br J Dermatol. 2023;188:228-236.
    >> Share

  598. GJERSVIK P
    Merkel cell carcinoma: aggressive, rare and on the rise.
    Br J Dermatol. 2023;188:162.
    >> Share

  599. KING B, Mostaghimi A, Shimomura Y, Zlotogorski A, et al
    Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
    Br J Dermatol. 2023;188:218-227.
    >> Share

  600. SMITH CM, Hambly R, Gatault S, Iglesias-Martinez LF, et al
    B-cell-derived transforming growth factor-beta may drive the activation of inflammatory macrophages and contribute to scarring in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:290-310.
    >> Share

  601. SANZ J, Gao JL, King DS, Modest AM, et al
    Prevalence of rosacea in transgender and gender-diverse populations: a retrospective cohort study.
    Br J Dermatol. 2023;188:304-306.
    >> Share

  602. BISSONNETTE R
    Safety of baricitinib in patients with alopecia areata.
    Br J Dermatol. 2023;188:163.
    >> Share

  603. GOVENDER K, Sibanda W, Lenzy Y, Dlova NC, et al
    The efficacy of learning programmes on hairstylists and barbers in the early detection of alopecia and scalp disorders in South Africa.
    Br J Dermatol. 2023;188:308-309.
    >> Share

  604. STEELE L, Innes S, Oldham J, Cunningham M, et al
    Safety outcomes for topical corticosteroid use in eczema herpeticum: a single-centre retrospective cohort study.
    Br J Dermatol. 2023;188:295-297.
    >> Share

  605. ALHEGGI A, McGrath JA, Hubbard L, Greenblatt DT, et al
    Treatment of multifactorial anaemia in adults with severe epidermolysis bullosa using intravenous ferric carboxymaltose: a single institution, observational, retrospective study.
    Br J Dermatol. 2023;188:306-307.
    >> Share

  606. ELEFTHERIADOU V, Bergqvist C, Kechichian E, Shourick J, et al
    Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials.
    Br J Dermatol. 2023;188:247-258.
    >> Share

  607. BROWN-KORSAH JB, Omar D, Wang X, Taylor SC, et al
    Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database.
    Br J Dermatol. 2023;188:299-301.
    >> Share

  608. MCSWEENEY SM, Rayinda T, McGrath JA, Tziotzios C, et al
    Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper.
    Br J Dermatol. 2023;188:195-197.
    >> Share

  609. CHEN ML, Rotemberg V, Lester JC, Novoa RA, et al
    Evaluation of diagnosis diversity in artificial intelligence datasets: a scoping review.
    Br J Dermatol. 2023;188:292-294.
    >> Share

  610. SYMANZIK C, John SM
    Occupational exposure to cobalt nanoparticles: potential implications on risk assessment and preventive measures.
    Br J Dermatol. 2023;188:161-162.
    >> Share

  611. BERKING C
    Update on the management of Bowen disease with a focus on patients' needs.
    Br J Dermatol. 2023;188:166.
    >> Share

  612. CHANPRAPAPH K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, et al
    A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
    Br J Dermatol. 2023;188:268-277.
    >> Share

  613. BELLEFEUILLE G, Paiewonsky B, Khalid B, Freese RL, et al
    Inflammatory induration in hidradenitis suppurativa and application to severity assessment.
    Br J Dermatol. 2023;188:309-310.
    >> Share

  614. WU Y, Gu C, Wang S, Yin H, et al
    Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
    Br J Dermatol. 2023 Feb 9:ljad032. doi: 10.1093.
    >> Share

  615. BORGHI A, D'Abundo L, Bassi C, Lupini L, et al
    A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma.
    Br J Dermatol. 2023 Feb 4:ljad024. doi: 10.1093.
    >> Share

    January 2023
  616. THORLACIUS L, Alam M
    A milestone reached for lichen sclerosus trial outcome standardisation.
    Br J Dermatol. 2023 Jan 27:ljad025. doi: 10.1093.
    >> Share

  617. MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
    Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
    >> Share

  618. KVIST-HANSEN A, Perez-Alos L, Al-Sofi RF, Heftdal LD, et al
    Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.
    Br J Dermatol. 2023 Jan 27:ljad023. doi: 10.1093.
    >> Share

  619. SIMPSON RC, Kirtschig G, Selk A, von Seitzberg S, et al
    Core outcome domains for lichen sclerosus: a CORALS initiative consensus statement.
    Br J Dermatol. 2023 Jan 26:ljac145. doi: 10.1093.
    >> Share

  620. SIMPSON RC
    Safety of tralokinumab in atopic dermatitis.
    Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
    >> Share

  621. GROLLEAU C, Le Cleach L, Shourick J, Sbidian E, et al
    Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs.
    Br J Dermatol. 2023 Jan 26:ljac142. doi: 10.1093.
    >> Share


  622. A new genetic cause for woolly hair and skin fragility.
    Br J Dermatol. 2023;188:e8.
    >> Share


  623. Clinical trial of Oleogel-S10 (birch bark extract gel) in epidermolysis bullosa.
    Br J Dermatol. 2023;188:e4.
    >> Share


  624. Lived experiences of patients with hidradenitis suppurativa-related pain.
    Br J Dermatol. 2023;188:e6.
    >> Share


  625. Providing new insights into the causes of large-to-giant congenital melanocytic naevi.
    Br J Dermatol. 2023;188:e7.
    >> Share

  626. KOGAME T, Yonekura S, Lovato P, Hirata M, et al
    Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
    Br J Dermatol. 2023;188:146-148.
    >> Share

  627. STARK MS
    Deficiencies in mismatch DNA repair: providing the soil for large-to-giant congenital melanocytic naevus development.
    Br J Dermatol. 2023;188:5.
    >> Share

  628. BERTOLD C, Martel P, Passeron T, Bahadoran P, et al
    Pigmented demodicosis presenting as lentigo maligna diagnosed by reflectance confocal microscopy.
    Br J Dermatol. 2023;188:149-150.
    >> Share

  629. WANG H, Lin Z
    Identification of the underlying gene for Flegel disease: another 'two-hit' genodermatosis?
    Br J Dermatol. 2023;188:7-8.
    >> Share

  630. MELLERIO JE
    EASE-y does it: Oleogel-S10 for epidermolysis bullosa wounds.
    Br J Dermatol. 2023;188:10-11.
    >> Share

  631. OKUN MM
    The promise of personalized medicine for hidradenitis suppurativa.
    Br J Dermatol. 2023;188:3.
    >> Share

  632. JACKSON A, Moss C, Chandler KE, Balboa PL, et al
    Biallelic TUFT1 variants cause woolly hair, superficial skin fragility and desmosomal defects.
    Br J Dermatol. 2023;188:75-83.
    >> Share

  633. ORENSTEIN LAV, Salame N, Siira MR, Urbanski M, et al
    Pain experiences among those living with hidradenitis suppurativa: a qualitative study.
    Br J Dermatol. 2023;188:41-51.
    >> Share

  634. MOSS C, Roked F, Davis PJ, Khan M, et al
    Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study.
    Br J Dermatol. 2023;188:139-140.
    >> Share

  635. KEARNEY N, Kirby B
    The devastating impact of hidradenitis suppurativa on employment.
    Br J Dermatol. 2023;188:9-10.
    >> Share

  636. THACI D, Vender R, de Rie MA, Conrad C, et al
    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Br J Dermatol. 2023;188:22-31.
    >> Share

  637. MIRALI S, Yeung J
    Does bimekizumab stand the test of time for psoriasis?
    Br J Dermatol. 2023;188:5-6.
    >> Share

  638. SCHNEIDER-BURRUS S, Kalus S, Fritz B, Wolk K, et al
    The impact of hidradenitis suppurativa on professional life.
    Br J Dermatol. 2023;188:122-130.
    >> Share

  639. ZHANG J, Schuttelaar MLA
    Water and adult eczema: the hard truth?
    Br J Dermatol. 2023;188:e1.
    >> Share

  640. AUBERT H, Arlegui H, De Rycke Y, Bachelez H, et al
    Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
    Br J Dermatol. 2023;188:150-152.
    >> Share

  641. WEI B, Gu J, Gao B, Bao Y, et al
    Deficient mismatch repair is detected in large-to-giant congenital melanocytic naevi: providing new insight into aetiology and diagnosis.
    Br J Dermatol. 2023;188:64-74.
    >> Share

  642. YUMICEBA V, Spielmann M
    When too much is too much: noncoding duplications in skin disorders.
    Br J Dermatol. 2023;188:e2-e3.
    >> Share

  643. JAGLE S, Hsu HH, Juratli HA, Zimmer AD, et al
    Pathogenic variants in the SPTLC1 gene cause hyperkeratosis lenticularis perstans.
    Br J Dermatol. 2023;188:94-99.
    >> Share

  644. BROWN AC, Earp EM, Veitch D, Wernham A, et al
    The top 10 research priorities for skin cancer surgery in the UK: results of a James Lind Alliance Priority Setting Partnership.
    Br J Dermatol. 2023;188:141-142.
    >> Share

  645. VINCENT R, Ormerod E, Gollins CE, Rai N, et al
    Semi-virtual patch testing: the future?
    Br J Dermatol. 2023;188:137-139.
    >> Share

  646. OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
    Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;188:145-146.
    >> Share

  647. GABES M, Donhauser T, Kann G, Masur C, et al
    Burden of disease: assessing quality-of-life impacts in hyperhidrosis.
    Br J Dermatol. 2023;188:143-145.
    >> Share

  648. SHIONOYA A, Yoto Y, Hida T, Ishikawa A, et al
    Bacillus Calmette-Guerin-induced lupus vulgaris in a patient with Mendelian susceptibility to mycobacterial disease caused by a novel STAT1 variation.
    Br J Dermatol. 2023;188:142-143.
    >> Share

  649. HAMBLY R, Gatault S, Smith CM, Iglesias-Martinez LF, et al
    B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
    Br J Dermatol. 2023;188:52-63.
    >> Share

  650. ZHOU L, Shao L, Gao S, Cui C, et al
    Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
    Br J Dermatol. 2023;188:112-121.
    >> Share

  651. CLARK A, Murphy MJ, King B, Cohen JM, et al
    Patient perspectives on the lived experience of granuloma annulare.
    Br J Dermatol. 2023;188:134-136.
    >> Share

  652. KRAKOWSKI I, Habel H, Nielsen K, Ingvar C, et al
    Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
    Br J Dermatol. 2023;188:32-40.
    >> Share

  653. VAN EGMOND S, de Vere Hunt I, Cai ZR, Rizk N, et al
    The perspectives of 606 US dermatologists on active surveillance for low-risk basal cell carcinoma.
    Br J Dermatol. 2023;188:136-137.
    >> Share

  654. KERN JS, Sprecher E, Fernandez MF, Schauer F, et al
    Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
    Br J Dermatol. 2023;188:12-21.
    >> Share


  655. Patients with melanoma and diabetes benefit from metformin treatment.
    Br J Dermatol. 2023;188:e5.
    >> Share

  656. FISCHER J, Alter S
    Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing.
    Br J Dermatol. 2023;188:8-9.
    >> Share

  657. ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
    Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
    Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
    >> Share

  658. PADOVESE V, Fuller LC, Griffiths CEM, Maurer T, et al
    Migrant skin health - Perspectives from the Migrant Health Summit, Malta, 2022.
    Br J Dermatol. 2023 Jan 19:ljad001. doi: 10.1093.
    >> Share

  659. MAUL JT, Frohlich F, Maul LV, Stunnenberg R, et al
    Access to psoriasis treatment in Brazil and Chile: A cross-sectional multi-centre ;Global Healthcare Study on Psoriasis.
    Br J Dermatol. 2023 Jan 19:ljac128. doi: 10.1093.
    >> Share

  660. BRAVO FG
    Assessing the use of biologic therapy for psoriasis in Latin America.
    Br J Dermatol. 2023 Jan 13:ljad003. doi: 10.1093.
    >> Share

  661. FOSTIER W, Holt G, Sampson J, Rajan N, et al
    Folliculin inactivation and cutaneous leiomyosarcoma in Birt-Hogg-Dube syndrome.
    Br J Dermatol. 2023 Jan 11:ljac138. doi: 10.1093.
    >> Share

  662. SWIFT T
    Peristomal Skin Complications: New Materials Needed to Ease the Ostomy Care Market.
    Br J Dermatol. 2023 Jan 11:ljad006. doi: 10.1093.
    >> Share

  663. ALABAS OA, Mason KJ, Yiu ZZN, Hampton PJ, et al
    Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
    Br J Dermatol. 2023 Jan 6:ljad004. doi: 10.1093.
    >> Share

  664. YEW YW, Apfelbacher CJ
    Validation of novel diagnostic criteria for atopic dermatitis in an adult and elderly Chinese population.
    Br J Dermatol. 2023 Jan 5:ljac143. doi: 10.1093.
    >> Share

    December 2022
  665. QUIRKE-MCFARLANE S, Weinman J, Cook ES, Yiu ZZN, et al
    Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
    Br J Dermatol. 2022 Dec 23:ljac144. doi: 10.1093.
    >> Share

  666. SO C, McCarthy D, Watts CG, Kearney C, et al
    Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia.
    Br J Dermatol. 2022 Dec 22:ljac111. doi: 10.1093.
    >> Share

  667. CICHY J
    Compartmentalized response of the human epidermis to staphylococci.
    Br J Dermatol. 2022 Dec 21:ljac125. doi: 10.1093.
    >> Share

  668. VEGAS LP, Claudepierre P
    Trajectories of comorbidities in patients with psoriasis: a question to be answered.
    Br J Dermatol. 2022 Dec 21:ljac126. doi: 10.1093.
    >> Share

  669. PERRIER F, Robsahm TE, Ghiasvand R, Borch KB, et al
    No association between physical activity and primary melanoma thickness in a cohort of Norwegian women.
    Br J Dermatol. 2022 Dec 21:ljac136. doi: 10.1093.
    >> Share

  670. LAN J, Huang Q, Yang L, Li Y, et al
    Effects of ambient air pollution on outpatient visits for psoriasis in Wuhan, China: a time-series analysis.
    Br J Dermatol. 2022 Dec 19:ljac124. doi: 10.1093.
    >> Share

  671. ADESANYA EI, Matthewman J, Schonmann Y, Hayes JF, et al
    Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis.
    Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093.
    >> Share

  672. HUGHES O, Shelton KH, Penny H, Thompson AR, et al
    Parent and child experience of skin conditions: Relevance for the provision of mindfulness-based interventions.
    Br J Dermatol. 2022 Dec 15:ljac129. doi: 10.1093.
    >> Share

  673. KEZIC S, van der Molen HF
    Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention.
    Br J Dermatol. 2022 Dec 14:ljac127. doi: 10.1093.
    >> Share

  674. YUE W, Cheng D, Sun Z, Shen Y, et al
    Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
    Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
    >> Share

  675. SAETRE R, Gotfredsen JL, Nonboe P, Hansen HD, et al
    An ostomy baseplate with a skin-protection technology reduces peristomal skin complications: a randomized controlled trial (the ATTRACT study).
    Br J Dermatol. 2022 Dec 8:ljac122. doi: 10.1093.
    >> Share

  676. FLOHR C
    How we treat atopic dermatitis now and how that will change over the next 5 years.
    Br J Dermatol. 2022 Dec 7:ljac116. doi: 10.1093.
    >> Share

  677. PLATAIS C, Lalagianni N, Momen S, Ormond M, et al
    Efficacy of hydroxychloroquine in oral lichen planus: a retrospective review.
    Br J Dermatol. 2022 Dec 3:ljac113. doi: 10.1093.
    >> Share

  678. MROWIETZ U, Augustin M
    Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization.
    Br J Dermatol. 2022;187:1007-1008.
    >> Share


  679. A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials.
    Br J Dermatol. 2022;187:e196-e221.
    >> Share

  680. PHILPOTT M
    Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia.
    Br J Dermatol. 2022;187:845.
    >> Share

  681. LAX SJ, Drucker AM
    How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?
    Br J Dermatol. 2022;187:838.
    >> Share

  682. KRIDIN K, Hammers CM
    Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid.
    Br J Dermatol. 2022;187:843-844.
    >> Share

  683. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    On the potential beneficial effects of indoor tanning: reply from the authors.
    Br J Dermatol. 2022;187:1057-1058.
    >> Share

  684. MIDGETTE B, Strunk A, Akilov O, Alavi A, et al
    Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.
    Br J Dermatol. 2022;187:927-935.
    >> Share

  685. CAPOZZA K, Vastrup A, Proctor A, Roberts A, et al
    The sound of silence: where are the voices of patients in eczema guideline development?
    Br J Dermatol. 2022;187:1005-1006.
    >> Share

  686. REHMAN R, Haque M, Ceresnie M, Hamzavi IH, et al
    Dermatological considerations and culturally sensitive recommendations for women who wear the hijab.
    Br J Dermatol. 2022;187:1003-1004.
    >> Share

  687. LIU J, Chen Z, Hu L, Song Z, et al
    Three new founder mutations in Chinese patients with Nagashima-type palmoplantar keratoderma.
    Br J Dermatol. 2022;187:1043-1045.
    >> Share

  688. VERMEER MCSC, Al-Shinnag M, Sillje HHW, Gaytan AE, et al
    A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation.
    Br J Dermatol. 2022;187:1045-1048.
    >> Share

  689. SILVERTHORNE CA, Bowen C, Lord J, McHugh N, et al
    A qualitative study of patients' experiences of screening for psoriatic arthritis.
    Br J Dermatol. 2022;187:1035-1037.
    >> Share

  690. LINDQVIST PG, Epstein E, Landin-Olsson M
    On the potential beneficial effects of indoor tanning.
    Br J Dermatol. 2022;187:1057.
    >> Share

  691. MOSTMANS Y, Smith V, Cutolo M, Melsens K, et al
    Nailfold videocapillaroscopy and serum vascular endothelial growth factor in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment.
    Br J Dermatol. 2022;187:1017-1019.
    >> Share

  692. MATARD B, Bourrat E, Cavalie M, Chiaverini C, et al
    Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association.
    Br J Dermatol. 2022;187:1026-1028.
    >> Share

  693. JI-XU A, Lei DK, Worswick S, Maloney NJ, et al
    Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.
    Br J Dermatol. 2022;187:1024-1026.
    >> Share

  694. KOPTYEV J, Strunk A, Garg A
    Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa.
    Br J Dermatol. 2022;187:1015-1017.
    >> Share

  695. COOK MK, Perche PO, White JC, Feldman SR, et al
    Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study.
    Br J Dermatol. 2022;187:1013-1015.
    >> Share

  696. LIU Q, Tang Y, Huang Y, Wang J, et al
    Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/beta-catenin signalling pathways.
    Br J Dermatol. 2022;187:936-947.
    >> Share

  697. GABES M, Ragamin A, Baker A, Kann G, et al
    Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
    Br J Dermatol. 2022;187:919-926.
    >> Share

    November 2022
  698. HU C, Jansen PW
    Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
    Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
    >> Share

  699. KOKOLAKIS G, Warren RB, Strober B, Blauvelt A, et al
    Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Br J Dermatol. 2022 Nov 29:ljac089. doi: 10.1093.
    >> Share

  700. ABUABARA K, Langan SM
    Atopic dermatitis across the life course.
    Br J Dermatol. 2022 Nov 18:ljac072. doi: 10.1093.
    >> Share

  701. TRIER AM, Kim BS
    Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
    Br J Dermatol. 2022 Nov 18:ljac016. doi: 10.1093.
    >> Share

  702. CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
    Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
    Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
    >> Share

  703. SCHELL SL, Cong Z, Sennett ML, Gettle SL, et al
    Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
    Br J Dermatol. 2022 Nov 17:ljac096. doi: 10.1093.
    >> Share

  704. IBRAHIM N, Jovic M, Ali S, Williams N, et al
    The epidemiology, healthcare and societal burden of basal cell carcinoma in Wales 2000-2018: a retrospective nationwide analysis.
    Br J Dermatol. 2022 Nov 17:ljac090. doi: 10.1093.
    >> Share

  705. WEISSHAAR E, Bentz P, Haufe E, Heinrich L, et al
    Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
    Br J Dermatol. 2022 Nov 17:ljac070. doi: 10.1093.
    >> Share

  706. GRINNELL M, Concha J, Feng R, Keyes E, et al
    Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis.
    Br J Dermatol. 2022 Nov 17:ljac091. doi: 10.1093.
    >> Share

  707. ROSENO NAL, Lorup EH, Richardson C, Alarcon I, et al
    Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study.
    Br J Dermatol. 2022 Nov 11:ljac086. doi: 10.1093.
    >> Share

  708. WITTLICH M, Westerhausen S, Strehl B, Versteeg H, et al
    The GENESIS-UV study on ultraviolet radiation exposure levels in 250 occupations to foster epidemiological and legislative efforts to combat nonmelanoma skin cancer.
    Br J Dermatol. 2022 Nov 11:ljac093. doi: 10.1093.
    >> Share

  709. HE X, Shi H
    How does acral melanoma respond to immunotherapy?
    Br J Dermatol. 2022 Nov 10:ljac035. doi: 10.1093.
    >> Share

  710. VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
    The association between atopic dermatitis, cognitive function and school performance in children and young adults.
    Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
    >> Share


  711. Measuring the effects of treatments for capillary malformations (vascular birthmarks).
    Br J Dermatol. 2022;187:e173-e192.
    >> Share

  712. EVRENOGLOU T
    Stratification according to disease severity can better reveal the relative effectiveness of treatments for acne vulgaris.
    Br J Dermatol. 2022;187:637-638.
    >> Share

  713. FLEDDERUS AC, Gout HA
    A core outcome set for pressure ulcers: an important step towards standardized outcome reporting of prevention strategies.
    Br J Dermatol. 2022;187:634-635.
    >> Share

  714. FROELUNDE AS, Vestergaard C
    Prurigo nodularis: the epidemiology of an under-recognized disease.
    Br J Dermatol. 2022;187:e171-e172.
    >> Share

  715. GIAMARELLOS-BOURBOULIS EJ
    Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita.
    Br J Dermatol. 2022;187:e170-e171.
    >> Share

  716. ORCHARD D
    Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
    Br J Dermatol. 2022;187:630-631.
    >> Share

  717. HARRS C, van den Akker PC, Baardman R, Duipmans JC, et al
    The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry.
    Br J Dermatol. 2022;187:824-826.
    >> Share

  718. CHOSIDOW O, Beylot-Barry M, Corgibet F, Jouan N, et al
    Isotretinoin: reasserting its public health value at the population level, addressing potential neuropsychiatric risk at the individual level.
    Br J Dermatol. 2022;187:831-832.
    >> Share

  719. LOPEZ DJ, Singh A, Waidyatillake NT, Su JC, et al
    The association between domestic hard water and eczema in adults from the UK Biobank cohort study.
    Br J Dermatol. 2022;187:704-712.
    >> Share

  720. MALOVITSKI K, Meijers O, Cohen-Barak E, Bergman J, et al
    Heterozygous variants in the integrin subunit beta 4 gene (ITGB4) cause autosomal dominant nail dystrophy.
    Br J Dermatol. 2022;187:826-828.
    >> Share

  721. BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
    Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
    Br J Dermatol. 2022;187:815-817.
    >> Share

  722. RING HC, Egeberg A, Zachariae C, Thomsen SF, et al
    Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy.
    Br J Dermatol. 2022;187:813-815.
    >> Share

  723. MAVRANEZOULI I, Daly CH, Welton NJ, Deshpande S, et al
    A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris.
    Br J Dermatol. 2022;187:639-649.
    >> Share

  724. ALI S, Pham H, Waterhouse M, Baxter C, et al
    The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial.
    Br J Dermatol. 2022;187:667-675.
    >> Share

  725. LECHNER A, Coleman S, Balzer K, Kirkham JJ, et al
    Core outcomes for pressure ulcer prevention trials: results of an international consensus study: Classification: Outcomes and qualitative research.
    Br J Dermatol. 2022;187:743-752.
    >> Share

  726. MARANGA A, Roche FC, Alausa M, McWilliams T, et al
    Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study.
    Br J Dermatol. 2022;187:802-804.
    >> Share

  727. BATAILLE P, Layese R, Claudepierre P, Paris N, et al
    Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
    Br J Dermatol. 2022;187:676-683.
    >> Share

  728. EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
    Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
    Br J Dermatol. 2022;187:659-666.
    >> Share

  729. GREENBLATT DT, Hubbard L, Bloor C, Card D, et al
    Vitamin C concentrations in patients with epidermolysis bullosa.
    Br J Dermatol. 2022;187:808-810.
    >> Share

  730. HUGHES O
    The need for psychological support in routine dermatological care across the UK.
    Br J Dermatol. 2022;187:778-779.
    >> Share

  731. GAMBICHLER T, Abu Rached N, Susok L, Becker JC, et al
    Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma.
    Br J Dermatol. 2022;187:806-808.
    >> Share

  732. SARASWAT N, Kumar S, Tripathy DM, Gopal MM, et al
    COVID-19-associated necrolytic acral erythema with postvaccination exacerbation in a seronegative patient.
    Br J Dermatol. 2022;187:e169.
    >> Share

  733. BOUDREAUX BW, Pincelli TP, Bhullar PK, Patel MH, et al
    Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Br J Dermatol. 2022;187:650-658.
    >> Share

  734. SANGHVI AP, Miles JA, Sayed C
    Clostridium difficile infection risk in patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:800-802.
    >> Share

  735. MERVIS JS, Maeng MM, Kirsner RS, Wester ST, et al
    Teprotumumab as a novel treatment for pretibial myxoedema.
    Br J Dermatol. 2022;187:795-797.
    >> Share

  736. SINGH R, Balogh EA, Senthilnathan A, Richardson IM, et al
    Fear of negative evaluation in patients with hidradenitis suppurativa is correlated with worse quality of life: an observational study.
    Br J Dermatol. 2022;187:788-790.
    >> Share

  737. BONDS PD, Huang J, Ike J, Mukherjee E, et al
    International Classification of Diseases codes do not capture all cases of hidradenitis suppurativa in the electronic health record: a retrospective cohort.
    Br J Dermatol. 2022;187:787-788.
    >> Share

  738. BELZER A, Silber A, Mehra S, Gilani S, et al
    Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T-DM1).
    Br J Dermatol. 2022;187:e168.
    >> Share

  739. LEWITT TM, Mammis-Gierbolini A, Parnell M, Sarfo A, et al
    International consensus definition of disease flare in hidradenitis suppurativa.
    Br J Dermatol. 2022;187:785-787.
    >> Share

    October 2022
  740. MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
    Cobalt nanoparticles cause allergic contact dermatitis in humans.
    Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
    >> Share

  741. TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
    Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
    Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
    >> Share

  742. ALI F, Smith CH, Mahil SK
    Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.
    Br J Dermatol. 2022 Oct 23:ljac049. doi: 10.1093.
    >> Share

  743. YOTSU RR, Fuller LC, Murdoch ME, Revankar C, et al
    World Health Organization strategic framework for integrated control and management of skin-related neglected tropical diseases: what does this mean for dermatologists?
    Br J Dermatol. 2022 Oct 20:ljac031. doi: 10.1093.
    >> Share


  744. The search for measurable predictors linked with negative health complications in psoriasis.
    Br J Dermatol. 2022;187:e158-e167.
    >> Share

  745. TZELLOS T
    Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:462-463.
    >> Share

  746. PANDYA AG, Ezzedine K
    Noticeability of vitiligo is in the eye of the beholder.
    Br J Dermatol. 2022;187:461-462.
    >> Share

  747. DESSINIOTI C
    Advances in acne clinical research: a new class of topical treatment for moderate-to-severe facial acne.
    Br J Dermatol. 2022;187:455-456.
    >> Share

  748. CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
    Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
    Br J Dermatol. 2022;187:619-622.
    >> Share

  749. MISERY L
    Chronic prurigo.
    Br J Dermatol. 2022;187:464-471.
    >> Share

  750. RENERT-YUVAL Y, Correa da Rosa J, Garcet S, Pavel AB, et al
    Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
    Br J Dermatol. 2022;187:539-547.
    >> Share

  751. DARRIGADE AS, Oules B, Sohier P, Jullie ML, et al
    Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: 'specific' patterns in a series of 192 patients.
    Br J Dermatol. 2022;187:615-617.
    >> Share

  752. POTTIER C, Eymieux S, Blanchard-Laumonnier E, Robert J, et al
    Loose anagen hair syndrome: take a closer look!
    Br J Dermatol. 2022;187:e156.
    >> Share

  753. YUKSEL YT, Edslev SM, Janstrup AK, Goldeman MS, et al
    Colonization with Staphylococcus aureus in healthcare workers: consequences of hand eczema.
    Br J Dermatol. 2022;187:609-611.
    >> Share

  754. TAYLOR MT, Bordeaux ZA, Deng J, Parthasarathy V, et al
    Association between prurigo nodularis and substance use disorders.
    Br J Dermatol. 2022;187:608-609.
    >> Share

  755. RING HC, Yao Y, Maul JT, Ingram JR, et al
    The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study.
    Br J Dermatol. 2022;187:523-530.
    >> Share

  756. BATCHELOR JM, Gran S, Leighton P, Howells L, et al
    Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.
    Br J Dermatol. 2022;187:548-556.
    >> Share

  757. DANIEL SR, Gandhi K, Anastassopoulos KP, Pandya AG, et al
    Impact of nonsegmental vitiligo on patients' health-related quality of life in the United States.
    Br J Dermatol. 2022;187:603-606.
    >> Share

  758. KLEIN EJ, Shapiro J, Piraccini B, Cummins D, et al
    Giving a voice: dermatologists' legislative advocacy for patients with hair loss.
    Br J Dermatol. 2022;187:582-583.
    >> Share

  759. PICARDO M, Cardinali C, La Placa M, Lewartowska-Bialek A, et al
    Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.
    Br J Dermatol. 2022;187:507-514.
    >> Share

  760. HAGAN PG, Bouazzi D, Nyarko G, Dartey ES, et al
    Prevalence of Hidradenitis Suppurativa in Berekum, Ghana.
    Br J Dermatol. 2022;187:586-587.
    >> Share

    September 2022
  761. GRAU-PEREZ M, Garcia-Doval I
    Differences in cutaneous manifestations of COVID-19 during the Delta and Omicron waves revealed using the ZOE app.
    Br J Dermatol. 2022 Sep 23. doi: 10.1111/bjd.21868.
    >> Share

  762. SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
    Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
    Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
    >> Share

  763. PUIG L
    Psoriasis treatment: no more room on the summit?
    Br J Dermatol. 2022 Sep 5. doi: 10.1111/bjd.21848.
    >> Share

  764. KIM RW, Barta K, Begolka WS, Capozza K, et al
    The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
    >> Share

  765. SIVALINGAM V, Tamber K
    Understanding the impact of life with vulval lichen sclerosus.
    Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21846.
    >> Share

  766. LEE H, Kwon O
    Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random.
    Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21838.
    >> Share


  767. Revolutionizing Atopic Dermatitis, 9-11 April 2022.
    Br J Dermatol. 2022;187:e80-e155.
    >> Share

  768. WILSON BN, Shah R, Menzer C, Aleisa A, et al
    Consensus on the Clinical Management of Chronic Radiation Dermatitis and Radiation Fibrosis: A Delphi Survey.
    Br J Dermatol. 2022 Sep 1. doi: 10.1111/bjd.21852.
    >> Share

  769. APFELBACHER C
    Closing a gap: an investigator global assessment for use in hidradenitis suppurativa clinical trials.
    Br J Dermatol. 2022;187:e79.
    >> Share

  770. PAVLOVSKY M, Peled A, Sarig O, Astman N, et al
    Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence.
    Br J Dermatol. 2022;187:392-400.
    >> Share

  771. GOULDEN V, Ling TC, Babakinejad P, Dawe R, et al
    British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022.
    Br J Dermatol. 2022;187:295-308.
    >> Share

  772. AARTS P, van der Zee HH
    Damage in hidradenitis suppurativa: receiving the deserved attention.
    Br J Dermatol. 2022;187:282-283.
    >> Share

  773. FAZEL S, Paljarvi T
    Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data': reply from authors.
    Br J Dermatol. 2022;187:450-451.
    >> Share

  774. CHANG R, Lai CC, Hung YM, Wang SI, et al
    Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data'.
    Br J Dermatol. 2022;187:450.
    >> Share

  775. GARG A, Krueger JG
    Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies.
    Br J Dermatol. 2022;187:414-415.
    >> Share

  776. DI CESARE A, Nikolakis G, Kanni T, Giamarellos-Bourboulis EJ, et al
    Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study.
    Br J Dermatol. 2022;187:428-430.
    >> Share

  777. PENNITZ A, Kinberger M, Avila Valle G, Passeron T, et al
    Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials.
    Br J Dermatol. 2022;187:309-317.
    >> Share

  778. MERHI R, Canu D, Barnetche T, Duchez E, et al
    Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo.
    Br J Dermatol. 2022;187:422-424.
    >> Share

  779. KLEIN B, Treudler R, Dumann K, Boldt A, et al
    Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.
    Br J Dermatol. 2022;187:419-422.
    >> Share

  780. GRINNELL M, Keyes E, Diaz D, Vazquez T, et al
    Mycophenolate mofetil and methotrexate efficacy in dermatomyositis.
    Br J Dermatol. 2022;187:437-438.
    >> Share

  781. JIANG SW, Kwock JT, Liu B, Petty AJ, et al
    High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
    Br J Dermatol. 2022;187:417-419.
    >> Share

  782. CHEN F, Deng D, Pan C, Yao Z, et al
    Detection and characterization of low-level mosaicism among clinically unaffected parents of 'sporadic' epidermolysis bullosa simplex cases.
    Br J Dermatol. 2022;187:441-443.
    >> Share

  783. FRITSCHE M, Okun M, Kirby JS
    Damage in hidradenitis suppurativa: a narrative review emphasizing the need for a novel outcome measure.
    Br J Dermatol. 2022;187:288-294.
    >> Share

  784. HASAN ZU, Ahmed I, Matin RN, Homer V, et al
    Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
    Br J Dermatol. 2022;187:324-337.
    >> Share

    August 2022
  785. KEMPF W
    Follicular T helper cells and cutaneous T-cell lymphomas.
    Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
    >> Share

  786. MOLHO-PESSACH V, Hartshtark S, Merims S, Lotem M, et al
    Giant congenital melanocytic nevus with a novel CUX1-BRAF fusion mutation treated with trametinib.
    Br J Dermatol. 2022 Aug 28. doi: 10.1111/bjd.21851.
    >> Share

  787. BALAK DMW, Rissmann R
    Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave.
    Br J Dermatol. 2022 Aug 22. doi: 10.1111/bjd.21813.
    >> Share

  788. NALDI L, Cazzaniga S
    The chicken or the egg: disentangling the relationship between smoking, alcohol consumption and psoriasis using Mendelian randomization.
    Br J Dermatol. 2022 Aug 21. doi: 10.1111/bjd.21805.
    >> Share

  789. LIU Y, Banka S, Huang Y, Hardman-Smart J, et al
    Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21842.
    >> Share

  790. LANDIS MN, Arya M, Smith S, Draelos Z, et al
    Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
    >> Share

  791. KAWSAR A, Edwards C, Patel P, Heywood RM, et al
    Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21836.
    >> Share

  792. LEVIN NA, Rashighi M
    Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21808.
    >> Share

  793. MCCOY K, DeSimone J
    Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumor response to PD-1 inhibitor.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21831.
    >> Share

  794. CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
    Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
    >> Share

  795. KIM RW, Barta K, Begolka WS, Capozza K, et al
    Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
    >> Share

  796. HASAN SB, Gendra R, James J, Morris D, et al
    Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa.
    Br J Dermatol. 2022 Aug 12. doi: 10.1111/bjd.21821.
    >> Share

  797. RANUM A, Freese R, Ramesh V, Pearson DR, et al
    Lichen sclerosus in female patients is associated with an increased risk of metabolic syndrome and cardiovascular comorbidities: A retrospective cohort review.
    Br J Dermatol. 2022 Aug 10. doi: 10.1111/bjd.21811.
    >> Share

  798. BELL KJL, Nijsten T
    Melanoma overdiagnosis: why it matters and what can be done about it.
    Br J Dermatol. 2022 Aug 5. doi: 10.1111/bjd.21750.
    >> Share

  799. CATALA A, Clavo Escribano P, Riera J, Martin-Ezquerra G, et al
    Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases.
    Br J Dermatol. 2022 Aug 2. doi: 10.1111/bjd.21790.
    >> Share

  800. FENG Y, Lu Y, Wang H
    Leucoderma secondary to wig wearing.
    Br J Dermatol. 2022;187:e64.
    >> Share


  801. Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
    Br J Dermatol. 2022;187:e69-e76.
    >> Share

  802. GARG A, Zema C, Kim K, Gao W, et al
    Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.
    Br J Dermatol. 2022;187:203-210.
    >> Share

  803. BIRABAHARAN M, Kaelber DC, Orme CM, Paravar T, et al
    Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination.
    Br J Dermatol. 2022;187:271-273.
    >> Share

  804. LIU Y, Tan Y, Liu J, Song Z, et al
    Novel and founder variants of SERPINA12 in Chinese patients with autosomal recessive palmoplantar keratoderma.
    Br J Dermatol. 2022;187:267-270.
    >> Share

  805. DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
    Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
    Br J Dermatol. 2022;187:234-243.
    >> Share

  806. JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
    Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
    Br J Dermatol. 2022;187:265-267.
    >> Share

  807. BAE JM, Kim M, Han JH, Lee S, et al
    Preventive effect of levodopa on vitiligo development: a nationwide case-control study.
    Br J Dermatol. 2022;187:259-261.
    >> Share

  808. RING HC, Thomsen SF
    The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:274.
    >> Share

  809. YUKSEL YT, Ibler K, Agner T, Ofenloch R, et al
    Validation of the Danish version of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ).
    Br J Dermatol. 2022;187:256-258.
    >> Share

  810. DE VERE HUNT I, Halley M, Sum K, Yekrang K, et al
    A qualitative exploration of the experiences of itch for adults living with epidermolysis bullosa.
    Br J Dermatol. 2022;187:261-263.
    >> Share

  811. BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
    Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
    Br J Dermatol. 2022;187:246-248.
    >> Share

  812. SINGH R, Mohammed A, Senthilnathan A, Feldman SR, et al
    Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study.
    Br J Dermatol. 2022;187:250-251.
    >> Share

  813. MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
    Epidemiology of prurigo nodularis in England: a retrospective database analysis.
    Br J Dermatol. 2022;187:188-195.
    >> Share

    July 2022
  814. SCHNEIDER AM, Nelson AM
    Impaired epidermal barriers in congenital ichthyoses house a changing microbial landscape.
    Br J Dermatol. 2022 Jul 29. doi: 10.1111/bjd.21746.
    >> Share

  815. VAN DER SCHOOT LS, Atalay S, Otero ME, Kievit W, et al
    Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21797.
    >> Share

  816. WANG L, Rocas D, Dalle S, Sako N, et al
    Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
    >> Share

  817. SHARIATMADARI I, Matteucci P, Barreda A, O'Toole L, et al
    Response to 'British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021': Vismodegib and indications for its use.
    Br J Dermatol. 2022 Jul 23. doi: 10.1111/bjd.21788.
    >> Share

  818. ORMEROD AD
    Predicting the outcome of psoriasis treatment.
    Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21747.
    >> Share

  819. VISCONTI A, Murray B, Rossi N, Wolf J, et al
    Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App.
    Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21784.
    >> Share

  820. LAURENT C, Lefevre G, Kahn JE, Staumont-Salle D, et al
    Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21782.
    >> Share

  821. NIKOLAOU V, Apalla Z, Carrera C, Fattore D, et al
    Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21781.
    >> Share

  822. CHOON SE, Wright AK, Griffiths CEM, Tey KE, et al
    Incidence and prevalence of psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in Teleprimary Care (TPC(R)) clinical information system from 2010 to 2020.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21768.
    >> Share

  823. NAGTZAAM IF, van Leersum FS, Kouwenberg LCM, Blok MJ, et al
    STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis shows genetic heterogeneity.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21775.
    >> Share

  824. MOHAMAD J, Sarig O, Beattie P, Malovitski K, et al
    A unique skin phenotype resulting from a large heterozygous deletion spanning six keratin genes.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21766.
    >> Share

  825. YANG N, Chen L, Shao J, Jiang F, et al
    Dupilumab with concomitant JAK inhibitor: A novel treatment strategy for atopic dermatitis with poor response to dupilumab.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21776.
    >> Share

  826. ROCCUZZO G, Fava P, Avallone G, Aquino C, et al
    Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21772.
    >> Share

  827. ARNOLD S, Fernando S, Rees S
    Living with Vulval Lichen Sclerosus: a qualitative interview study.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21777.
    >> Share

  828. FROMME M, Schneider CV, Schlapbach C, Cazzaniga S, et al
    Comorbidities in lichen planus by phenome-wide association study in two biobank population cohorts.
    Br J Dermatol. 2022 Jul 12. doi: 10.1111/bjd.21762.
    >> Share

  829. RUIZ GENAO DP, Carretero G, Rivera-Diaz R, Carrascosa JM, et al
    Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the Biobadaderm registry.
    Br J Dermatol. 2022 Jul 12. doi: 10.1111/bjd.21763.
    >> Share

  830. BLAUVELT A, Kimball AB, Augustin M, Okubo Y, et al
    Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blinded, Placebo-Controlled, Randomised Withdrawal, Phase III Trial (OASIS-1).
    Br J Dermatol. 2022 Jul 6. doi: 10.1111/bjd.21743.
    >> Share


  831. British Society for Investigative Dermatology Virtual Annual Meeting, 29-31 March 2021.
    Br J Dermatol. 2022;187:e1-e63.
    >> Share

  832. HUNT N
    Identity and psychological distress in alopecia areata.
    Br J Dermatol. 2022;187:9-10.
    >> Share

  833. SCHUTTELAAR MLA
    A new avenue for treatment of chronic hand eczema.
    Br J Dermatol. 2022;187:7-8.
    >> Share

  834. RAVENCROFT J, Eichenfield L
    Isotretinoin does not contribute to increased neuropsychiatric risk in the overall acne population, but risk management during treatment remains essential.
    Br J Dermatol. 2022;187:8-9.
    >> Share

  835. PALJARVI T, McPherson T, Luciano S, Herttua K, et al
    Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data.
    Br J Dermatol. 2022;187:64-72.
    >> Share

  836. MACBETH AE, Holmes S, Harries M, Chiu WS, et al
    The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care.
    Br J Dermatol. 2022;187:73-81.
    >> Share

  837. WORM M, Thyssen JP, Schliemann S, Bauer A, et al
    The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Br J Dermatol. 2022;187:42-51.
    >> Share

  838. WANG J, Ram-Wolff C, Dobos G, Al Hage J, et al
    Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
    Br J Dermatol. 2022;187:129-131.
    >> Share

  839. HEWITT RM, Bundy C, Newi AL, Chachos E, et al
    How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast).
    Br J Dermatol. 2022;187:82-88.
    >> Share


  840. Eumelanin Human Skin Colour Scale: proof-of-concept study.
    Br J Dermatol. 2022;187:vi.
    >> Share

    June 2022
  841. WEI J, Zhu J, Xu H, Zhou D, et al
    Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21718.
    >> Share

  842. SANTANDREA G, Valli R, Ragazzi M, Castagnetti F, et al
    Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21715.
    >> Share

  843. VONK J, de Wit JG, Voskuil FJ, Koldijk M, et al
    Fluorescence molecular imaging using cetuximab-800CW in cutaneous squamous cell carcinoma surgery: a proof-of-concept study.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21722.
    >> Share

  844. SCHNEEWEISS MC, Kirchgesner J, Wyss R, Jin Y, et al
    Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study.
    Br J Dermatol. 2022 Jun 19. doi: 10.1111/bjd.21704.
    >> Share

  845. CALBET-LLOPART N, Combalia M, Kiroglu A, Potrony M, et al
    Common genetic variants associated with melanoma risk or naevus count in wild-type MC1R melanoma patients.
    Br J Dermatol. 2022 Jun 14. doi: 10.1111/bjd.21707.
    >> Share

  846. AGUILAR-DURAN S, Mee J, Popat S, Heelan K, et al
    Atezolizumab-induced linear IgA bullous dermatosis.
    Br J Dermatol. 2022 Jun 7. doi: 10.1111/bjd.21653.
    >> Share

  847. FAN R, Leasure AC, Maisha FI, Little AJ, et al
    Thyroid disorders associated with lichen sclerosus: A case-control study in the All of Us research program.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21702.
    >> Share

  848. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
    >> Share

  849. ITO M, Kamata M, Uchida H, Egawa S, et al
    Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21701.
    >> Share

  850. PENG C, Jian X, Xie Y, Li L, et al
    Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.
    Br J Dermatol. 2022;186:997-1009.
    >> Share

  851. OFENLOCH R, Grochulska K, Mettang T, Weisshaar E, et al
    The incidence of chronic itch in patients on haemodialysis and associated factors.
    Br J Dermatol. 2022;186:1052-1054.
    >> Share

  852. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    >> Share

  853. BETTUZZI T, Hua C, Diaz E, Colin A, et al
    Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
    Br J Dermatol. 2022;186:1037-1039.
    >> Share

  854. MIN MS, Kus K, Wei N, Kassamali B, et al
    Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study.
    Br J Dermatol. 2022;186:1035-1037.
    >> Share

    May 2022
  855. THAM KC, Lefferdink R, Duan K, Lim SS, et al
    Distinct skin microbiome community structures in congenital ichthyosis.
    Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21687.
    >> Share

  856. SINGAL A, Mehta S
    Eumelanin Human Skin Colour Scale: a novel concept with potential for further refinement.
    Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21652.
    >> Share

  857. MIURA H, Fujiwara S
    Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser.
    Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21633.
    >> Share

  858. RICCI F, Abeni D
    Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21598.
    >> Share

  859. OLSEN CM
    International surveillance of trends in melanoma survival: the impact of morphology.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21651.
    >> Share

  860. HAN J, O'Neal S, Gravely A, Linos E, et al
    United States Academic Dermatologists' Attitudes Towards Active Surveillance for Basal Cell Carcinoma.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21675.
    >> Share

  861. MARTIN-MORO F, Martin-Rubio I, Garcia-Vela JA
    TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21678.
    >> Share

  862. CORBETT M, Ramessur R, Marshall D, Acencio ML, et al
    Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21677.
    >> Share

  863. KAMMINGA NCW, van der Veldt AAM, Joosen MCW, de Joode K, et al
    Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
    Br J Dermatol. 2022 May 21. doi: 10.1111/bjd.21670.
    >> Share

  864. LANGAN EA, Kunstner A
    The gastrointestinal microbiome and psoriasis: more food for thought.
    Br J Dermatol. 2022 May 20. doi: 10.1111/bjd.21618.
    >> Share

  865. BALAK DMW, Lambert J
    Weighing in on weight-based secukinumab dosing for psoriasis.
    Br J Dermatol. 2022 May 16. doi: 10.1111/bjd.21607.
    >> Share

  866. PONTES FSC, Pereira GG, da Silva Santos PS, Pontes HAR, et al
    Isotretinoin and herpes simplex virus infection.
    Br J Dermatol. 2022 May 11. doi: 10.1111/bjd.21610.
    >> Share

  867. SCHEEL CH, Rached NA, Gambichler T
    Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21591.
    >> Share

  868. WHITEMAN DC, Olsen CM, MacGregor S, Law MH, et al
    The effect of screening on melanoma incidence and biopsy rates.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21649.
    >> Share

  869. COLE EF, Mustin DE, Feldman RJ
    The Effect of Race and Fitzpatrick Skin Type on Bullous Pemphigoid Disease Area Index (BPDAI) Scores.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21648.
    >> Share

  870. CAPON F
    New genetic and clinical features of neonatal inflammatory skin and bowel disease 1.
    Br J Dermatol. 2022 May 6. doi: 10.1111/bjd.21589.
    >> Share

  871. DISSEMOND J, Romanelli M
    Inflammatory skin diseases and wounds.
    Br J Dermatol. 2022 May 6. doi: 10.1111/bjd.21619.
    >> Share

  872. SCHUMMER P, Schilling B
    How representative are data from global trials on programmed death-1 blockade in melanoma?
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21621.
    >> Share

  873. LEONARDI-BEE J, Drucker AM
    Systemic treatments for psoriasis: not another network meta-analysis!
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21601.
    >> Share

  874. MAGIN P, Fisher K
    Body dysmorphic disorder, skin diseases and psychological morbidity: common and complex.
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21586.
    >> Share

  875. CARRERA C, Podlipnik S
    Does acral melanoma need a distinctive prognostic staging system?
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21585.
    >> Share

  876. BACHELEZ H
    Is heat shock protein 90 inhibition a relevant treatment strategy for psoriasis?
    Br J Dermatol. 2022;186:771-772.
    >> Share

  877. BAARDMAN R, Bolling MC
    The importance of accurate epidemiological data of epidermolysis bullosa.
    Br J Dermatol. 2022;186:765-766.
    >> Share

  878. KLEIN TM
    Content validity of five single-item instruments in adolescents with alopecia areata.
    Br J Dermatol. 2022;186:763-764.
    >> Share


  879. Findings from a survey about hidradenitis suppurativa in the Netherlands.
    Br J Dermatol. 2022;186:e200-e219.
    >> Share

  880. KEARNEY N, Kirby B
    The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed.
    Br J Dermatol. 2022;186:767-768.
    >> Share

  881. SIBBALD C, Alhusayen R
    Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox.
    Br J Dermatol. 2022;186:768-769.
    >> Share

  882. ALAVI A, Hamzavi I, Brown K, Santos LL, et al
    Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
    Br J Dermatol. 2022;186:803-813.
    >> Share

  883. CHEN CW, Wei JC
    Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
    Br J Dermatol. 2022;186:910-911.
    >> Share

  884. GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
    Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
    Br J Dermatol. 2022;186:911.
    >> Share

  885. WONGVIBULSIN S, Parthasarathy V, Pahalyants V, Murphy W, et al
    Latent class analysis identification of prurigo nodularis comorbidity phenotypes.
    Br J Dermatol. 2022;186:903-905.
    >> Share

  886. PETROF G, Papanikolaou M, Martinez AE, Mellerio JE, et al
    The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database.
    Br J Dermatol. 2022;186:843-848.
    >> Share

  887. BARRANCA A, Debarbieux S, Tancrede-Bohin E, Saillard C, et al
    A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features.
    Br J Dermatol. 2022;186:899-902.
    >> Share

  888. YATSUZUKA K, Murakami M
    Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.
    Br J Dermatol. 2022;186:908.
    >> Share

  889. CRO S, Smith CH
    Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.
    Br J Dermatol. 2022;186:909-910.
    >> Share

  890. MACEY J, Kitchen H, Aldhouse NVJ, Edson-Heredia E, et al
    A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
    Br J Dermatol. 2022;186:849-860.
    >> Share

  891. WAKKEE M
    Polygenic risk scores for melanoma: a stepwise process towards clinical implementation.
    Br J Dermatol. 2022;186:768.
    >> Share

    April 2022
  892. FLOREZ ID
    Clinical practice guidelines for psoriasis: which ones are the best?
    Br J Dermatol. 2022 Apr 29. doi: 10.1111/bjd.21605.
    >> Share

  893. SAMIMI M
    Is 5-fluorouracil the best candidate for topical chemoprevention of skin cancers in organ transplant recipients?
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21602.
    >> Share

  894. ZHUANG K, Ran Y
    Primary cutaneous nocardiosis caused by a novel Nocardia species.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21599.
    >> Share

  895. CHOON SE, Bachelez H
    Time to accurately determine the burden of generalized pustular psoriasis at the population level.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21588.
    >> Share

  896. LEMMENS VEPP, Louwman MWJ
    Basal cell carcinoma, an often unjustly overlooked healthcare challenge.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21587.
    >> Share

  897. BIEBER T, Reich K, Paul C, Tsunemi Y, et al
    Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
    >> Share

  898. RAMESSUR R, Corbett M, Marshall D, Acencio ML, et al
    Biomarkers of disease progression in people with psoriasis: a scoping review.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21627.
    >> Share

  899. LAQUER V, Parra V, Lacour JP, Takahashi H, et al
    IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.
    >> Share

  900. JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
    Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.
    >> Share

  901. KWAN Z, Anand RL, Mallipeddi R, Ali FR, et al
    The utility of negative histopathological analysis of debulk specimens during Mohs micrographic surgery for basal cell carcinoma.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21613.
    >> Share

  902. GRIFFIN LR, Ryan S, Ramsay B
    Response to 'Patients with nodular prurigo commonly have pre-existing psychological disease that requires treatment concomitant with cutaneous therapies'.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21616.
    >> Share

  903. REICH K, Cullen E, Weinberg M
    Maintenance of response in moderate-to-severe psoriasis after withdrawal of the IL-17A and IL-17F nanobody sonelokimab - Is there a role for IL-17F in disease reoccurrence?
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21617.
    >> Share

  904. SIMPSON EL, Bissonnette R, Paller AS, King B, et al
    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
    >> Share

  905. SOLIMAN YS, Mieczkowska K, Zhu TR, Hossain O, et al
    Characterizing Basal Cell Carcinoma in Hispanic Individuals Undergoing Mohs Micrographic Surgery: A 7-year Retrospective Review at an Academic Institution in the Bronx.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21614.
    >> Share

  906. MANOLACHE L, Finlay AY
    Should self-help interventions become routine in psoriasis therapy?
    Br J Dermatol. 2022 Apr 19. doi: 10.1111/bjd.21584.
    >> Share

  907. MAKINO T, Sugiyama H, Oshima M, Mizawa M, et al
    Cutaneous gnathostomiasis caused by Gnathostoma spinigerum.
    Br J Dermatol. 2022 Apr 15. doi: 10.1111/bjd.21007.
    >> Share

  908. HARVIMA IT, Harvima RJ
    Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new 'revolutionary' therapeutics?
    Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21583.
    >> Share

  909. GJERSVIK P
    The future is hard to predict, even for patients with cutaneous squamous cell carcinoma.
    Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21291.
    >> Share

  910. BLOME C, von Stulpnagel CC, Augustin M, Mrowietz U, et al
    Measuring patient-relevant benefits in psoriasis with the Patient Benefit Index: Development and preliminary validation of a 10-item short form.
    Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21593.
    >> Share

  911. NIELSEN ML, Nymand LK, Thomsen SF, Thyssen JP, et al
    Delay in diagnosis and treatment of patients with psoriasis - a population-based cross-sectional study.
    Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21594.
    >> Share

  912. LOFT N, Skov L, Richardson C, Trivedi V, et al
    A nationwide population-based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark.
    Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21595.
    >> Share

  913. NALDI L
    Going global with assessing the acne burden: is the evidence worth the effort?
    Br J Dermatol. 2022;186:605.
    >> Share


  914. Revolutionizing Atopic Dermatitis, 11-13 December 2021.
    Br J Dermatol. 2022;186:e135-e185.
    >> Share

  915. BARBAROT S
    Targeting the itch-scratch vicious circle in atopic eczema.
    Br J Dermatol. 2022;186:608.
    >> Share

  916. SUBRAMANIAM KS, Antoniou MN, McGrath JA, Lwin SM, et al
    The potential of gene therapy for recessive dystrophic epidermolysis bullosa.
    Br J Dermatol. 2022;186:609-619.
    >> Share

  917. KASPERKIEWICZ M, Strong R, Mead K, Yale M, et al
    COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
    Br J Dermatol. 2022;186:737-739.
    >> Share

  918. LUCKY AW, Pope E
    Pregnancy in epidermolysis bullosa: long-awaited guidelines of care.
    Br J Dermatol. 2022;186:602-603.
    >> Share

  919. SARKANY RPE, Canfield M, Morgan M, Foster L, et al
    Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour.
    Br J Dermatol. 2022;186:713-720.
    >> Share

  920. GAMBICHLER T, Hamdani N, Budde H, Sieme M, et al
    Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies.
    Br J Dermatol. 2022;186:728-731.
    >> Share

  921. CHEN H, Zhang TC, Yin XL, Man JY, et al
    Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019.
    Br J Dermatol. 2022;186:673-683.
    >> Share

  922. RAMIREZ-GARCIALUNA JL, Wang SC, Yangzom T, Piguet V, et al
    Use of thermal imaging and a dedicated wound-imaging smartphone app as an adjunct to staging hidradenitis suppurativa.
    Br J Dermatol. 2022;186:723-726.
    >> Share

  923. RASHID H, Meijer JM, Bolling MC, Horvath B, et al
    Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid.
    Br J Dermatol. 2022;186:721-723.
    >> Share

  924. CHEN XQ, Zheng DY, Xiao YY, Dong BL, et al
    Aetiology of tinea capitis in China: a multicentre prospective study.
    Br J Dermatol. 2022;186:705-712.
    >> Share

  925. GREENBLATT DT, Pillay E, Snelson K, Saad R, et al
    Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline.
    Br J Dermatol. 2022;186:620-632.
    >> Share

    March 2022
  926. DADZIE OE, Sturm RA, Fajuyigbe D, Petit A, et al
    The Eumelanin Human Skin Colour Scale: A Proof-of-Concept Study.
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21277.
    >> Share

  927. KATO J, Namikawa K, Uehara J, Nomura M, et al
    Prognoses of melanoma patients who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: A multicenter retrospective study.
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21276.
    >> Share

  928. DI CARLO V, Stiller CA, Eisemann N, Bordoni A, et al
    Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21274.
    >> Share

  929. SOWTER P, Santibanez-Koref M, Jackson MS, Borthwick GM, et al
    Response to 'Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours'.
    Br J Dermatol. 2022 Mar 24. doi: 10.1111/bjd.20970.
    >> Share

  930. FISCHER K, Aringer M, Steininger J, Heil J, et al
    Improvement of cutaneous inflammation and panniculitis in dermatomyositis patients by the JAK-inhibitor baricitinib.
    Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21252.
    >> Share

  931. KURTANSKY NR, Manci RN, Bello DM, Adamson AS, et al
    Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma.
    Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251.
    >> Share

  932. STEFANOVIC N, Fitzmaurice CJ, Ormond P, Irvine AD, et al
    Risk Factors for Distant Metastasis in Cutaneous Squamous Cell Carcinoma.
    Br J Dermatol. 2022 Mar 22. doi: 10.1111/bjd.21250.
    >> Share

  933. BAI X, Shoushtari AN, Betof Warner A, Si L, et al
    Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study.
    Br J Dermatol. 2022 Mar 16. doi: 10.1111/bjd.21241.
    >> Share

  934. JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
    Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.
    >> Share

  935. TODBERG T, Egeberg A, Zachariae C, Sorensen N, et al
    Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21245.
    >> Share

  936. REID C, Welsh C, Martin-Smith H, Dharmaprasad S, et al
    A Rapid Access Clinic for Psoriasis - First Experiences.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21242.
    >> Share

  937. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin' :reply from authors.
    Br J Dermatol. 2022 Mar 10. doi: 10.1111/bjd.21239.
    >> Share

  938. OYA K, Nakamura Y, Fujisawa Y, Nomura T, et al
    Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin'.
    Br J Dermatol. 2022 Mar 9. doi: 10.1111/bjd.21230.
    >> Share

  939. KOREN J, Mburu S, Trigos D, Damiani G, et al
    Generalised pustular psoriasis: the case for rare disease and orphan designation.
    Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21231.
    >> Share

  940. REICH K, Baraliakos X, Coates LC, Elewski B, et al
    Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis.
    Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21233.
    >> Share

  941. XIA P, Pasquali L, Gao C, Srivastava A, et al
    miR-378a regulates keratinocyte responsiveness to IL-17A in psoriasis.
    Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21232.
    >> Share

  942. ZAMAGNI F, Bucchi L, Mancini S, Crocetti E, et al
    The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.21051.
    >> Share

  943. NOVAK N, Cabanillas B
    Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.
    >> Share

  944. PARAGH G
    Epidermal melanoma prognostic factors: a link to paracrine transforming growth factor-beta signalling.
    Br J Dermatol. 2022 Mar 2. doi: 10.1111/bjd.20981.
    >> Share

  945. ZAGAR T, Hlaca N, Brajac I, Prpic-Massari L, et al
    Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
    Br J Dermatol. 2022;186:e110.
    >> Share


  946. A comparison of the different questionnaires used to measure health-related quality of life in patients with dermatological conditions.
    Br J Dermatol. 2022;186:e111-e133.
    >> Share

  947. CONCHA JSS, Afarideh M, Werth VP
    Postinflammatory hyperpigmentation and erythema: new insights into the pathogenesis.
    Br J Dermatol. 2022;186:390-391.
    >> Share

  948. LAYTON AM, McDonald BS, Mohd Mustapa MF, Levell NJ, et al
    National Institute for Health and Care Excellence (NICE) acne guideline: what's the latest for dermatologists?
    Br J Dermatol. 2022;186:426-428.
    >> Share

  949. DOBOS G, Assaf C
    Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
    Br J Dermatol. 2022;186:387-388.
    >> Share

  950. AOKI V, Miyamoto D
    Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?
    Br J Dermatol. 2022;186:386-387.
    >> Share

  951. SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
    British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
    Br J Dermatol. 2022;186:398-413.
    >> Share

  952. GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
    Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
    Br J Dermatol. 2022;186:583-585.
    >> Share

  953. TISACK A, Fotouhi A, Fidai C, Friedman BJ, et al
    Response to 'A clinical and biological review of keratoacanthoma': reply from authors.
    Br J Dermatol. 2022;186:592-593.
    >> Share

  954. MAZZONI D, Muir J
    Considerations in the management of keratoacanthoma.
    Br J Dermatol. 2022;186:592.
    >> Share

  955. SIMPSON K, Low ZM, Yap T, Kern JS, et al
    Ultralow-dose rituximab in pemphigus: a single-centre experience.
    Br J Dermatol. 2022;186:581-583.
    >> Share

  956. VELLAICHAMY G, Kohli I, Zubair R, Yin C, et al
    An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics.
    Br J Dermatol. 2022;186:508-519.
    >> Share

  957. BAILEY AMJ, Li HO, Burns K, Cheng W, et al
    Targeting the opioid pathway for the treatment of chronic kidney disease-associated pruritus: a systematic review and meta-analysis of randomized controlled trials.
    Br J Dermatol. 2022;186:575-577.
    >> Share

  958. XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
    Transcriptomic changes during stage progression of mycosis fungoides.
    Br J Dermatol. 2022;186:520-531.
    >> Share

  959. PERSSON MSM, Begum N, Grainge MJ, Harman KE, et al
    The global incidence of bullous pemphigoid: a systematic review and meta-analysis.
    Br J Dermatol. 2022;186:414-425.
    >> Share

    February 2022
  960. LEE A, Stanley G, Gardiner MD, Batchelor JM, et al
    An international clinician survey CompAring Non-Absorbable Versus Absorbable sutures for Skin surgery: the CANVAS Study.
    Br J Dermatol. 2022 Feb 22. doi: 10.1111/bjd.21062.
    >> Share

  961. NAVRAZHINA K, Frew JW, Grand D, Williams SC, et al
    IL-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Br J Dermatol. 2022 Feb 22. doi: 10.1111/bjd.21060.
    >> Share

  962. MIRALI S, Fabusiwa K, Linos E
    Safety in numbers: risankizumab for moderate-to-severe psoriasis.
    Br J Dermatol. 2022 Feb 20. doi: 10.1111/bjd.20947.
    >> Share

  963. NGUYEN R
    Ocular conjunctivitis in biological therapies for atopic dermatitis.
    Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.
    >> Share

  964. HAN J, O'Neal S, Gravely A, Gupta R, et al
    Patients' attitudes towards active surveillance for basal cell carcinoma.
    Br J Dermatol. 2022 Feb 15. doi: 10.1111/bjd.21058.
    >> Share

  965. TANNENBAUM R, Strunk A, Garg A
    Age- and Sex- Adjusted Prevalence Estimates Among Pediatric Patients with Psoriasis in the United States.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21057.
    >> Share

  966. VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
    Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
    >> Share

  967. VAN COILE L, Verhaeghe E, Ongenae K, Brochez L, et al
    Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting are appropriate?
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21056.
    >> Share

  968. YEN H, Huang CH, Huang IH, Hung WK, et al
    Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP).
    Br J Dermatol. 2022 Feb 13. doi: 10.1111/bjd.21047.
    >> Share

  969. SANGERS TE, Wakkee M, Kramer-Noels EC, Nijsten T, et al
    Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: A nationwide pathology registry analysis.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21050.
    >> Share

  970. MASTORINO L, Roccuzzo G, Dapavo P, Siliquini N, et al
    Patients with psoriasis resistant to multiple biologic therapies: characteristics and definition of a difficult-to-treat population.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21048.
    >> Share

  971. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21046.
    >> Share

  972. FUTAMURA M
    Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.
    >> Share

  973. MARGOLIS DJ
    Atopic dermatitis: filaggrin and skin barrier dysfunction.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.
    >> Share

  974. BECHMAN K, Cook ES, Dand N, Yiu ZZN, et al
    Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.
    Br J Dermatol. 2022 Feb 1. doi: 10.1111/bjd.21042.
    >> Share

  975. GAO JM, Goiriz R, Rajpopat S, Goldsmith P, et al
    Occupational dermatoses during the second wave of the COVID-19 pandemic: a UK prospective study of 805 healthcare workers.
    Br J Dermatol. 2022;186:374-376.
    >> Share


  976. Different ways of estimating the amount of individual sun exposure.
    Br J Dermatol. 2022;186:e84-e109.
    >> Share

  977. LEIENDECKER L, Jung PS, Obenauf AC
    Targeting CD56 with an antibody-drug conjugate in Merkel cell carcinoma.
    Br J Dermatol. 2022;186:209-210.
    >> Share

  978. SCHELL SL, Nelson AM
    Are antimicrobial peptides a double-edged sword in hidradenitis suppurativa pathophysiology?
    Br J Dermatol. 2022;186:204-205.
    >> Share

  979. SINCLAIR R
    Alopecia areata: progress, but who pays?
    Br J Dermatol. 2022;186:206-207.
    >> Share

  980. VAN DER ZEE HH, van de Bunte M, van Straalen KR
    Management of mild hidradenitis suppurativa: our greatest challenge yet.
    Br J Dermatol. 2022;186:355-356.
    >> Share

  981. GLEESON D, Cliff S, Das M
    Eruptive keratoacanthomas associated with dupilumab therapy.
    Br J Dermatol. 2022;186:376-377.
    >> Share

  982. NAGOBA BS, Rayate AS, Patil NR, Gavkare AM, et al
    Citric acid treatment of infected venous eczema refractory to conventional treatment: a novel approach.
    Br J Dermatol. 2022;186:377-379.
    >> Share

  983. LEUS AJG, Horvath B, Terra JB, Diercks GFH, et al
    Eligibility criteria for programmed death receptor 1 inhibitors vs. real-world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck.
    Br J Dermatol. 2022;186:371-372.
    >> Share

  984. GAUDIN O, Milpied B, Papouin B, Hue S, et al
    Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
    Br J Dermatol. 2022;186:372-374.
    >> Share

  985. CARTER C, Martin K, Gordon C, Goulding JMR, et al
    Exploring the lived experience of women with rosacea: visible difference and psychological impact.
    Br J Dermatol. 2022;186:366-367.
    >> Share

  986. ESNAULT C, Leblond V, Martin C, Desgranges A, et al
    Adcitmer((R)) , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
    Br J Dermatol. 2022;186:295-306.
    >> Share

  987. FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
    Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
    Br J Dermatol. 2022;186:363-365.
    >> Share

  988. HASANAJ A, Zaki F, Harman KE, Grindlay D, et al
    Cause-specific mortality in people with bullous pemphigoid and pemphigus vulgaris: a systematic review and meta-analysis.
    Br J Dermatol. 2022;186:359-361.
    >> Share

  989. YAO Y, Frew JW, Thomsen SF, Ring HC, et al
    Antimicrobial peptides in hidradenitis suppurativa: a systematic review.
    Br J Dermatol. 2022;186:236-244.
    >> Share

  990. SOUEID L, Triguero-Mas M, Dalmau A, Barrera-Gomez J, et al
    Estimating personal solar ultraviolet radiation exposure through time spent outdoors, ambient levels and modelling approaches.
    Br J Dermatol. 2022;186:266-273.
    >> Share

  991. HARRIES M, Macbeth AE, Holmes S, Chiu WS, et al
    The epidemiology of alopecia areata: a population-based cohort study in UK primary care.
    Br J Dermatol. 2022;186:257-265.
    >> Share

    January 2022
  992. PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
    Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
    Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.
    >> Share

  993. LAM M, Monaghan C, Chan AW, Drucker AM, et al
    Characterization of discontinuation and nonpublication of phase 3 randomized clinical trials for psoriasis.
    Br J Dermatol. 2022 Jan 21. doi: 10.1111/bjd.21025.
    >> Share

  994. GEALE K, Schmitt-Egenolf M
    Severity of psoriasis - Time to disentangle severity from symptom control.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21023.
    >> Share

  995. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
    >> Share

  996. EBATA T
    Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis.
    Br J Dermatol. 2022 Jan 19:ljac082. doi: 10.1093.
    >> Share

  997. WEI X, Wu D, Chen Y, Li H, et al
    Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21026.
    >> Share

  998. MUFTIN Z, Gilbert P, Thompson AR
    A Randomised Controlled Feasibility Trial of Online Compassion-focused Self-Help for Psoriasis.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21020.
    >> Share

  999. KOZERA E, Stewart T, Gill K, De La Vega MA, et al
    Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.
    >> Share

  1000. YOSIPOVITCH G, Papp K, Forman S, Han G, et al
    The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.
    >> Share

  1001. SCHUT C, Dalgard FJ, Bewley A, Evers AWM, et al
    Body dysmorphia in common skin diseases: Results of an observational, cross-sectional multi-centre study among dermatological out-patients in 17 European countries.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21021.
    >> Share

  1002. SORENSEN ST, Nagy D, Lindahl LM, Farkas DK, et al
    Risk of Cancer in Patients with Psoriasis and Venous Thromboembolism: a Danish Population-based Cohort study 1996-2018.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21016.
    >> Share

  1003. SEMSARIAN CR, Ma T, Nickel B, Scolyer RA, et al
    Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
    Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21010.
    >> Share

  1004. HALLE A, De Becdelievre A, Funalot B, Labreze C, et al
    SCN10A variants associated with congenital Harlequin Syndrome.
    Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21011.
    >> Share

  1005. KODAMA S, Gupta D, Sullivan E, Rosenwasser N, et al
    Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors in children-A retrospective cohort study.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20980.
    >> Share

  1006. KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
    Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
    >> Share

  1007. SAMUELOV L, Sarig O, Malovitski K, Bergson S, et al
    Neonatal inflammatory skin and bowel disease type 1 caused by a complex genetic defect and responsive to combined anti-TNF-alpha and IL-12/23 blockade.
    Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20978.
    >> Share

  1008. GINDL A, Schotta AM, Berent S, Markowicz M, et al
    Persistent Lyme disease with cutaneous borrelia biofilm formation.
    Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20977.
    >> Share

  1009. CALABRESE L, Fiocco Z, Satoh TK, Peris K, et al
    Therapeutic potential of targeting IL-1 family cytokines in chronic inflammatory skin diseases.
    Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20975.
    >> Share

  1010. KEMPF W, Petrella T, Willemze R, Jansen P, et al
    Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
    Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
    >> Share

  1011. ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
    >> Share

  1012. ORMOND M, McParland H, Thakrar P, Donaldson A, et al
    Validation of an Oral Disease Severity Score for use in oral lichen planus.
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20968.
    >> Share

  1013. AUGUSTIN M, Reich K, Yamauchi P, Pinter A, et al
    Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial.
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20971.
    >> Share

  1014. LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
    Prevalence and incidence of generalised pustular psoriasis in Sweden - a population-based register study.
    Br J Dermatol. 2022 Jan 2. doi: 10.1111/bjd.20966.
    >> Share

  1015. MAGIN PJ, Tng ETV
    Specialists and generalists in skin disease management: educational, clinical and research imperatives.
    Br J Dermatol. 2022;186:1-2.
    >> Share

  1016. BLANCHARD G, Guenova E
    Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Br J Dermatol. 2022;186:15-16.
    >> Share


  1017. Psoriasis: From Gene to Clinic, 9(th) International Congress The Queen Elizabeth II Conference Centre, London, UK 9(th) -11(th) December 2021.
    Br J Dermatol. 2022;186:e2-e82.
    >> Share

  1018. NATSUGA K
    Prevention of chemotherapy-induced hair loss by peroxisome proliferator-activated receptor-gamma modulation.
    Br J Dermatol. 2022;186:14-15.
    >> Share

  1019. EZZEDINE K, Pandya AG
    British Association of Dermatologist guidelines: a lighthouse to help guide clinicians and researchers planning future clinical trials for vitiligo.
    Br J Dermatol. 2022;186:3-4.
    >> Share

  1020. FLEMING P
    Risankizumab vs. fumaric acid esters: a direct comparison.
    Br J Dermatol. 2022;186:4-5.
    >> Share

  1021. VAN STRAALEN KR, Gulliver W
    The expected missing heritability of hidradenitis suppurativa in perspective.
    Br J Dermatol. 2022;186:9-10.
    >> Share

  1022. HUGHES M, Denton CP
    The critical need for patient-reported outcome measures to assess the severity and impact of systemic sclerosis.
    Br J Dermatol. 2022;186:11-12.
    >> Share

  1023. GABES M
    The 'Chronic Itch Burden Scale': giving patients with chronic pruritus a voice.
    Br J Dermatol. 2022;186:10-11.
    >> Share

  1024. ABBAS LF, Joseph AK, Prasad S, Zhu JL, et al
    Revealing novel, latent subsets of patients with morphoea through principal component analysis.
    Br J Dermatol. 2022;186:193-195.
    >> Share

  1025. JABBOUR AJ, van Straalen KR, Colvin A, Prens EP, et al
    Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration.
    Br J Dermatol. 2022;186:183-185.
    >> Share

  1026. RAYINDA T, McSweeney SM, Dand N, Fenton DA, et al
    Clinical characteristics of male frontal fibrosing alopecia: a single-centre case series from London, UK.
    Br J Dermatol. 2022;186:195-197.
    >> Share

  1027. SIBEONI J, Dunogue B, Dupont A, Haiddar D, et al
    Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale.
    Br J Dermatol. 2022;186:96-105.
    >> Share

  1028. KJAERSGAARD ANDERSEN R, Clemmensen SB, Larsen LA, Hjelmborg JVB, et al
    Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins.
    Br J Dermatol. 2022;186:78-85.
    >> Share

  1029. ELEFTHERIADOU V, Atkar R, Batchelor J, McDonald B, et al
    British Association of Dermatologists guidelines for the management of people with vitiligo 2021.
    Br J Dermatol. 2022;186:18-29.
    >> Share

  1030. THEUNIS J, Nordon C, Falissard B, Orri M, et al
    Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus.
    Br J Dermatol. 2022;186:86-95.
    >> Share

    December 2021
  1031. MICEVIC G, Lo SN, Rajan N
    Targeting the neonatal Fc receptor in pemphigus: safety first.
    Br J Dermatol. 2021 Dec 27. doi: 10.1111/bjd.20939.
    >> Share

  1032. KAPPELIN J, Green AC, Ingvar A, Ahnlide I, et al
    Incidence and trends of basal cell carcinoma in Sweden: A population-based registry study.
    Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20964.
    >> Share

  1033. LOBATO-BEREZO A, Gonzalez-Farre M, Pujol RM
    Pustular frontal fibrosing alopecia: a new variant within the folliculitis decalvans and lichen planopilaris phenotypic spectrum?
    Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20962.
    >> Share

  1034. PUIG L, Costanzo A, Munoz-Elias EJ, Jazra M, et al
    The biological basis of disease recurrence in psoriasis: a historical perspective and current models.
    Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20963.
    >> Share

  1035. STEINBERG J, Iles MM, Lee JY, Wang X, et al
    Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20956.
    >> Share

  1036. DANBY SG, Andrew PV, Kay LJ, Pinnock A, et al
    Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema-prone, skin.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20955.
    >> Share

  1037. PRENS LM, Bouwman K, Troelstra LD, Prens EP, et al
    New Insights in Hidradenitis Suppurativa from a Population-based Dutch Cohort: Prevalence, Smoking Behaviour, Socioeconomic Status and Comorbidities.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20954.
    >> Share

  1038. THOMSON J, Hogan S, Leonardi-Bee J, Williams HC, et al
    Response to 'Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments': reply from the authors.
    Br J Dermatol. 2021 Dec 17. doi: 10.1111/bjd.20950.
    >> Share

  1039. VINERETSKY KA, Domingo-Musibay E, Karagas MR, Lazovich D, et al
    A functional variant in the immune signalling receptor NKG2D alters skin cancer risk.
    Br J Dermatol. 2021 Dec 8. doi: 10.1111/bjd.20943.
    >> Share

  1040. LUENGAS-MARTINEZ A, Paus R, Young HS
    A novel personalised treatment approach for psoriasis: anti-VEGF-A therapy.
    Br J Dermatol. 2021 Dec 8. doi: 10.1111/bjd.20940.
    >> Share

  1041. VENABLES ZC, Tokez S, Hollestein LM, Mooyaart AL, et al
    Validation of Four Cutaneous Squamous Cell Carcinoma Staging Systems Using Nationwide Data.
    Br J Dermatol. 2021 Dec 3. doi: 10.1111/bjd.20909.
    >> Share

  1042. GUELIMI R, Afach S, Regnaux JP, Bettuzzi T, et al
    Overlapping network meta-analyses on psoriasis systemic treatments: an overview, quantity does not make quality.
    Br J Dermatol. 2021 Dec 2. doi: 10.1111/bjd.20908.
    >> Share


  1043. Do anti-psoriatic drugs work better in women than men?
    Br J Dermatol. 2021;185:e200-e213.
    >> Share

  1044. WOLF P
    Systemic antipsoriatic treatment: do women respond better than men and if so, why?
    Br J Dermatol. 2021;185:1088-1089.
    >> Share

  1045. KOTB I
    Evidence for the long-term efficacy and safety of guselkumab.
    Br J Dermatol. 2021;185:1087-1088.
    >> Share

  1046. ORMEROD AD
    Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights.
    Br J Dermatol. 2021;185:1089-1090.
    >> Share

  1047. KINOSHITA-ISE M
    Refining the diagnosis and assessment methodology in frontal fibrosing alopecia.
    Br J Dermatol. 2021;185:1092-1093.
    >> Share

  1048. LEE HY
    Bullous pemphigoid: towards personalized care.
    Br J Dermatol. 2021;185:1093-1094.
    >> Share

  1049. HUFFMAN C, Cardis MA
    Image: Atypical chondrodermatitis nodularis due to in-ear headphones.
    Br J Dermatol. 2021;185:e199.
    >> Share

  1050. FINLAY AY, Griffiths TW, Belmo S, Chowdhury MMU, et al
    Why we should abandon the misused descriptor 'erythema'.
    Br J Dermatol. 2021;185:1240-1241.
    >> Share

  1051. NIKOLAKIS G, Kristandt A, Hauptmann M, Becker M, et al
    Efficacy of short-term intravenous clindamycin prior to oral clindamycin-rifampicin treatment in hidradenitis suppurativa: a retrospective case series.
    Br J Dermatol. 2021;185:1270-1272.
    >> Share

  1052. SUN H, Lim JS, Silva CF, Maczuga SA, et al
    Insurance coverage gap for treatment of melasma compared with rosacea: it pays to be light.
    Br J Dermatol. 2021;185:1252-1254.
    >> Share

  1053. WADA-IRIMADA M, Mizuashi M, Takahashi T, Tojo G, et al
    A retrospective study evaluating the outcomes of high-dose methylprednisolone pulse therapy for 483 patients with moderate-to-severe alopecia areata.
    Br J Dermatol. 2021;185:1267-1269.
    >> Share

  1054. WESTPHAL D, Garzarolli M, Sergon M, Horak P, et al
    High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
    Br J Dermatol. 2021;185:1186-1199.
    >> Share

  1055. DOOLAN BJ, Onoufriadis A, Kantaputra P, McGrath JA, et al
    WNT10A, dermatology and dentistry.
    Br J Dermatol. 2021;185:1105-1111.
    >> Share

  1056. THOMPSON LL, Yoon J, Chang MS, Polyakov NJ, et al
    Advanced care planning, code status and end-of-life care in patients with bullous pemphigoid.
    Br J Dermatol. 2021;185:1246-1247.
    >> Share

  1057. HEBERT V, Bastos S, Drenovska K, Meijer J, et al
    International multicentre observational study to assess the efficacy and safety of a 0.5 mg kg(-1) per day starting dose of oral corticosteroids to treat bullous pemphigoid.
    Br J Dermatol. 2021;185:1232-1239.
    >> Share

  1058. OLSEN EA, Harries M, Tosti A, Bergfeld W, et al
    Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).
    Br J Dermatol. 2021;185:1221-1231.
    >> Share

  1059. BEN ABDALLAH H, Bech R, Fogh K, Olesen AB, et al
    Comorbidities, mortality and survival in patients with pyoderma gangrenosum: a Danish nationwide registry-nested case-control study.
    Br J Dermatol. 2021;185:1169-1175.
    >> Share

    November 2021
  1060. DEAR K, Psomadakis C, Dost S, Lalagianni N, et al
    Cutaneous manifestations of PIMS-TS: a single centre experience.
    Br J Dermatol. 2021 Nov 29. doi: 10.1111/bjd.20907.
    >> Share

  1061. SINIKUMPU SP, Huilaja L
    Challenges of multidimensional atopic dermatitis.
    Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.
    >> Share

  1062. DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
    Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
    >> Share

  1063. SUN MD, Kentley J, Mehta P, Duzsa S, et al
    Accuracy of commercially available smartphone applications for the detection of melanoma.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20903.
    >> Share

  1064. CHUNG JG, Holtkamp H, Nieuwoudt M, Matthews H, et al
    The combination of Raman Spectroscopy and Mass Spectrometry to investigate cutaneous metallosis.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20902.
    >> Share

  1065. DAND N
    Genome-wide scan for structural variation underlying psoriasis.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20836.
    >> Share

  1066. CHALMERS RJG
    Recognizing psoriasis in children and adolescents: the DIPSOC study.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20825.
    >> Share

  1067. MARUSIC Z, Calonje E
    Skin adnexal tumours in a tertiary dermatopathology service.
    Br J Dermatol. 2021 Nov 15. doi: 10.1111/bjd.20816.
    >> Share

  1068. BERGAMASCHI D
    Autophagy protects from photoageing in skin fibroblasts.
    Br J Dermatol. 2021 Nov 15. doi: 10.1111/bjd.20822.
    >> Share

  1069. PARK JH, Yoon JE, Kim YH, Kim Y, et al
    The potential skin lightening candidate, senolytic drug ABT263, for photoageing pigmentation.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20893.
    >> Share

  1070. COSGAREA I, McConnell AT, Ewen T, Tang D, et al
    Melanoma secretion of TGFbeta-2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20889.
    >> Share

  1071. DE VERE HUNT I, van Egmond S, Nava V, Khodosh R, et al
    Telehealth for Older Adults with Skin Disease: A Qualitative Exploration of Dermatologists' Experiences & Recommendations for Improving Care.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20891.
    >> Share

  1072. MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
    Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
    >> Share

  1073. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
    >> Share

  1074. BREGNHOJ A, Thuesen KKH, Emmanuel T, Litman T, et al
    HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20880.
    >> Share

  1075. JABOURI H, Abbott RA
    Sustainability in skin cancer surgery.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20886.
    >> Share

  1076. MAZZONI D, Muir J
    Response to "Interventions for basal cell carcinoma: abridged Cochrane systematic reviews and GRADE assessments".
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20878.
    >> Share

  1077. PAPP KA, Gooderham MJ, Albrecht LE, Raymond MA, et al
    Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20885.
    >> Share

  1078. MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
    Early tumor response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20879.
    >> Share

  1079. CHIESA Z
    How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.
    >> Share

  1080. BATAILLE V, Puig S
    COVID-19 vaccines and skin manifestations.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20807.
    >> Share

  1081. BEN ABDALLAH H, Vestergaard C
    Atopic dermatitis, hypertension and cardiovascular disease.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.
    >> Share

  1082. CAZZANIGA S, Naldi L
    Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20776.
    >> Share

  1083. CAMARA NOS
    Do the gut and skin microbiomes share thoughts on melanoma development?
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20811.
    >> Share

  1084. GAMBICHLER T, Krogias C, Tischoff I, Tannapfel A, et al
    Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20824.
    >> Share

  1085. PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
    IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
    >> Share

  1086. LAMBERT WC, Sy CB, Madari AP, Schwartz RA, et al
    Perineal cutaneous basal cell carcinomas in patients with familial seronegative celiac disease: Report of three cases.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20870.
    >> Share

  1087. SCHREUDER K, Hollestein L, Nijsten TEC, Wakkee M, et al
    A nationwide study of the incidence and trends of first and multiple basal cell carcinoma in the Netherlands and prediction of future incidence.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20871.
    >> Share

  1088. KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
    Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
    >> Share

  1089. MAURUS K, Kosnopfel C, Kneitz H, Appenzeller S, et al
    Cutaneous epithelioid hemangiomas show somatic mutations in the MAPK pathway.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20869.
    >> Share

  1090. SZABO A, Brodszky V, Rencz F
    A comparative study on the measurement properties of DLQI, DLQI-R and Skindex-16.
    Br J Dermatol. 2021 Nov 1. doi: 10.1111/bjd.20765.
    >> Share


  1091. Patients who misuse alcohol have poorer responses to systemic treatments for psoriasis.
    Br J Dermatol. 2021;185:e179-e198.
    >> Share

  1092. HWANG E, Tomayko MM
    COVID-19 outcomes in patients with autoimmune blistering disease.
    Br J Dermatol. 2021;185:1048-1050.
    >> Share

  1093. HSIAO J, Shi V
    Hidradenitis suppurativa: redirecting a life trajectory.
    Br J Dermatol. 2021;185:878.
    >> Share

  1094. ADOTAMA P, Callender V, Kolla A, Young C, et al
    Comparing the clinical differences in white and black women with frontal fibrosing alopecia.
    Br J Dermatol. 2021;185:1074-1076.
    >> Share

  1095. TEIXEIRA MS, Gavazzoni Dias MFR, Vilar EAG, Pantaleao L, et al
    Histopathological differential diagnosis of frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution.
    Br J Dermatol. 2021;185:1069-1070.
    >> Share

  1096. SINIKUMPU SP, Vahanikkila H, Jokelainen J, Tasanen K, et al
    Male patients with rosacea have increased risk for migraine: a population-based study.
    Br J Dermatol. 2021;185:1058-1061.
    >> Share

  1097. PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
    Br J Dermatol. 2021;185:1035-1044.
    >> Share

  1098. CHU CB, Yang CC, Tsai SJ
    Global data analysis supports smoking as the fundamental element associated with geographical sex disparities in hidradenitis suppurativa.
    Br J Dermatol. 2021;185:1054-1056.
    >> Share

  1099. CROITORU D, Sibbald C, Alavi A, Brooks S, et al
    Challenging the association of hepatitis C and pyoderma gangrenosum.
    Br J Dermatol. 2021;185:1047-1048.
    >> Share

  1100. MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
    Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Br J Dermatol. 2021;185:999-1012.
    >> Share

  1101. HOWELLS L, Lancaster N, McPhee M, Bundy C, et al
    Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review.
    Br J Dermatol. 2021;185:921-934.
    >> Share

  1102. LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
    Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study.
    Br J Dermatol. 2021;185:945-951.
    >> Share

  1103. PRENS LM, Porter ML, Savage KT, Salian P, et al
    Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study.
    Br J Dermatol. 2021;185:1072-1074.
    >> Share

    October 2021
  1104. HOYER A, Rehbinder EM, Fardig M, Asad S, et al
    Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
    >> Share

  1105. VAN WINDEN MEC, Klosters FM, Hamaker M, Olde Rikkert MG, et al
    Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20833.
    >> Share

  1106. GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
    Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
    >> Share

  1107. OLIVER R, Krueger JG, Glatt S, Vajjah P, et al
    Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study.
    Br J Dermatol. 2021 Oct 23. doi: 10.1111/bjd.20827.
    >> Share

  1108. SBIDIAN E, Pina-Vegas L
    Head-to-head trials in psoriasis and psoriatic arthritis: how to conclude?
    Br J Dermatol. 2021 Oct 20. doi: 10.1111/bjd.20771.
    >> Share

  1109. GORDON KB, Lebwohl M, Papp KA, Bachelez H, et al
    Long-Term Safety of Risankizumab From 17 Clinical Trials in Patients With Moderate-to-Severe Plaque Psoriasis.
    Br J Dermatol. 2021 Oct 15. doi: 10.1111/bjd.20818.
    >> Share

  1110. WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
    Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
    >> Share

  1111. MONNET P, Herms F, Djermane M, Dalac S, et al
    Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20808.
    >> Share

  1112. HENDERSON BERG MH, Davison K, Popradi G
    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
    >> Share

  1113. PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
    Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
    >> Share

  1114. GOEBELER M, Bata-Csorgo Z, De Simone C, Didona B, et al
    Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20782.
    >> Share

  1115. EIGENTLER T
    Benefits of a nationwide population-based skin cancer screening programme - still a controversial debate.
    Br J Dermatol. 2021 Oct 4. doi: 10.1111/bjd.20709.
    >> Share

  1116. BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
    Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
    Br J Dermatol. 2021;185:838-839.
    >> Share

  1117. MURRELL DF, Patsatsi A, Stavropoulos P, Baum S, et al
    Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
    Br J Dermatol. 2021;185:745-755.
    >> Share

  1118. SHOURICK J, Ahmed M, Seneschal J, Passeron T, et al
    Development of a shared decision-making tool in vitiligo: an international study.
    Br J Dermatol. 2021;185:787-796.
    >> Share

  1119. HAW WY, Al-Janabi A, Arents BWM, Asfour L, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.
    Br J Dermatol. 2021;185:736-744.
    >> Share


  1120. Shared decision-making for vitiligo.
    Br J Dermatol. 2021;185:e158-e178.
    >> Share

  1121. STANDL M
    Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization.
    Br J Dermatol. 2021;185:694-695.
    >> Share

  1122. WAN J, Abuabara K
    Growing evidence for an association between inflammatory skin disease and chronic kidney disease.
    Br J Dermatol. 2021;185:693-694.
    >> Share

  1123. HO JSS, Asai Y
    Commentary on the British Association of Dermatologists guidelines for the management of people with rosacea 2021.
    Br J Dermatol. 2021;185:689-690.
    >> Share

  1124. SIL A, Panigrahi A, Pramanik JD
    Isolated cutaneous larva migrans over the scalp in a hod carrier.
    Br J Dermatol. 2021;185:e157.
    >> Share

  1125. VAN DER SCHOOT LS, van den Reek JMPA
    Data-driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine.
    Br J Dermatol. 2021;185:698-699.
    >> Share

  1126. DRUCKER AM, Shear NH
    Bruton tyrosine kinase inhibition warrants further study for pemphigus.
    Br J Dermatol. 2021;185:691-692.
    >> Share

  1127. FREW JW
    Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic.
    Br J Dermatol. 2021;185:696-697.
    >> Share

  1128. BRUNNER PM, Conrad C, Vender R, Grond S, et al
    Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
    Br J Dermatol. 2021;185:865-867.
    >> Share

  1129. SANCHEZ MARTINEZ EM, Murray G, Alfageme Roldan F, Garcia Ruiz R, et al
    Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study.
    Br J Dermatol. 2021;185:863-865.
    >> Share

  1130. YU W, Barrett J, Liu P, Parameswaran A, et al
    Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: assessment of sex and individual variability.
    Br J Dermatol. 2021;185:855-858.
    >> Share

  1131. RIQUELME-MC LOUGHLIN C, Iranzo P
    Subcutaneous rituximab for autoimmune bullous diseases.
    Br J Dermatol. 2021;185:870-871.
    >> Share

  1132. MA BC, Sahni VN, Edwards LD, Sahni DR, et al
    Response to 'A call to standardize the BCC:SCC ratio'.
    Br J Dermatol. 2021;185:868-869.
    >> Share

  1133. JIYAD Z, Marquart L, Green AC
    Response to 'A call to standardize the BCC:SCC ratio': reply from the authors.
    Br J Dermatol. 2021;185:869-870.
    >> Share

  1134. STEFANIS AJ, Arenberger P, Arenbergerova M, Gkalpakiotis S, et al
    Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment.
    Br J Dermatol. 2021;185:847-849.
    >> Share

  1135. QUEIROS C, Silva L, Miroux Catarino A, Labareda J, et al
    Topical imiquimod as neoadjuvant therapy before Mohs micrographic surgery for basal cell carcinoma in the head and neck region: findings from a large retrospective study.
    Br J Dermatol. 2021;185:851-853.
    >> Share

  1136. WALKER SL, Head MG, Middleton J, Cassell JA, et al
    Ivermectin in the management of a scabies outbreak in a long-term care facility.
    Br J Dermatol. 2021;185:868.
    >> Share

  1137. HAMPTON PJ, Berth-Jones J, Duarte Williamson CE, Hay R, et al
    British Association of Dermatologists guidelines for the management of people with rosacea 2021.
    Br J Dermatol. 2021;185:725-735.
    >> Share

  1138. JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
    Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021;185:815-824.
    >> Share

  1139. ALANI A, Kibbi N, Oliphant T
    Mohs micrographic surgery for patients living with HIV.
    Br J Dermatol. 2021;185:836-837.
    >> Share

  1140. ABDELRAZIK YT, Ali FM, Salek MS, Finlay AY, et al
    Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI).
    Br J Dermatol. 2021;185:711-724.
    >> Share

  1141. BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
    Relationship between atopic dermatitis, depression and anxiety: a two-sample Mendelian randomization study.
    Br J Dermatol. 2021;185:781-786.
    >> Share

  1142. CAO Y, Hong F, Conlon DM, Sidur L, et al
    Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa.
    Br J Dermatol. 2021;185:804-814.
    >> Share

    September 2021
  1143. FROMME JE, Zigrino P
    Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor.
    Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20756.
    >> Share

  1144. CHONG BF
    Guidance for providers on the treatment and management of cutaneous lupus erythematosus.
    Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20746.
    >> Share

  1145. OH Y, Markova A, Noor SJ, Rotemberg V, et al
    Standardized Clinical Photography Considerations in Patients Across Skin Tones.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20766.
    >> Share

  1146. NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
    Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
    >> Share

  1147. COTTER C, Solman L, Flohr C
    A national audit of oral propranolol for the treatment of Infantile Hemangiomas.
    Br J Dermatol. 2021 Sep 2. doi: 10.1111/bjd.20738.
    >> Share

    August 2021
  1148. CUST AE
    Strengthening melanoma prevention and early detection among people with type 2 diabetes.
    Br J Dermatol. 2021 Aug 18. doi: 10.1111/bjd.20633.
    >> Share

    July 2021
  1149. PROCOPIO-AZEVEDO AC, Rabello VBS, Muniz MM, Figueiredo-Carvalho MHG, et al
    Hypersensitivity reactions in sporotrichosis: A retrospective cohort of 325 patients from a reference hospital in Rio de Janeiro, Brazil (2005-2018).
    Br J Dermatol. 2021 Jul 14. doi: 10.1111/bjd.20646.
    >> Share

    June 2021
  1150. CARMIGNAC V, Salomon G, Severino-Freire M, Duffourd Y, et al
    Mosaic NEK9 mutation, fibrous dysplasia and premature puberty in nevus comedonicus syndrome.
    Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20603.
    >> Share

  1151. BUI H, Skiba PN, Breskin A, Sayed C, et al
    Hidradenitis Suppurativa Among Patients with Human Immunodeficiency Virus: Investigating Patient and Disease Characteristics, and Misdiagnosis.
    Br J Dermatol. 2021 Jun 22. doi: 10.1111/bjd.20591.
    >> Share

    May 2021
  1152. CLAESON M, Baade P, Marchetti M, Brown S, et al
    Comparative performance of predictors of death from thin (
    Br J Dermatol. 2021 May 12. doi: 10.1111/bjd.20480.
    >> Share

    April 2021
  1153. DESSINIOTI C, Geller AC, Whiteman DC, Garbe C, et al
    Not all melanomas are created equal: A review and call for more research into nodular melanoma.
    Br J Dermatol. 2021 Apr 16. doi: 10.1111/bjd.20388.
    >> Share

    January 2021
  1154. NAGORE E, Martinez-Garcia MA, Gomez-Olivas JD, Manrique-Silva E, et al
    Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: An observational multi-centric study in 443 patients with melanoma.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19813.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016